Wolcott-Rallison Syndrome

Mendelian MONDO:0009192 Pathograph 28 Show in embeddings browser Monogenic Diabetes

Wolcott-Rallison syndrome (WRS) is a rare autosomal recessive disorder caused by biallelic loss-of-function variants in EIF2AK3, which encodes the endoplasmic-reticulum transmembrane kinase PERK (PKR-like endoplasmic reticulum kinase). PERK phosphorylates the translation initiation factor eIF2-alpha to attenuate protein synthesis during the unfolded protein response; without it, cells with a high secretory or synthetic load cannot buffer endoplasmic reticulum stress and die by apoptosis. The pancreatic beta cell is the first and most consistently affected: PERK is required during fetal and early neonatal life for beta-cell expansion, differentiation, and proinsulin handling, so its loss produces permanent, non-autoimmune, insulin-dependent diabetes that presents before six months of age. The same loss of adaptive reserve produces multiple epiphyseal or spondyloepiphyseal dysplasia with growth retardation, and recurrent, stress-triggered episodes of acute hepatic failure that are the leading cause of death. Variable additional features include renal dysfunction, hypothyroidism, neutropenia with recurrent infections, exocrine pancreatic insufficiency, developmental delay, and craniocervical (os odontoideum) instability. WRS is now recognized as the most frequent cause of permanent neonatal diabetes in consanguineous populations. There is no disease-modifying therapy; management is insulin replacement, aggressive supportive treatment of hepatic crises, and liver or multi-organ transplantation, which improves survival.

Ask OpenScientist

Ask a research question about Wolcott-Rallison Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
8
Pathophys.
12
Phenotypes
2
Gaps
28
Pathograph
1
Genes
5
Medical Actions
1
Models
1
References
1
Deep Research
👪

Inheritance

1
Autosomal Recessive HP:0000007
WRS is autosomal recessive with a 25% recurrence risk for future siblings; heterozygous carrier parents are clinically unaffected. Consanguinity is the dominant driver of case load, and the disorder is the most frequent cause of permanent neonatal diabetes in consanguineous populations.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:23759358 SUPPORT Human Clinical
"Wolcott-Rallison syndrome (WRS) is caused by recessive EIF2AK3 gene mutations and characterized by permanent neonatal diabetes (PNDM), skeletal dysplasia, and recurrent hepatitis."
States the recessive inheritance and the defining triad.
?

Discussions and Knowledge Gaps

2
Is the fetal/neonatal beta-cell developmental requirement for PERK, demonstrated in Perk-knockout mice, the operative mechanism of the permanent diabetes in human WRS?
HUMAN MODEL MISMATCH wrs_beta_cell_developmental_mechanism_human_fidelity
Attached to
pathophysiology#ER-Stress-Induced Beta-Cell Failure
The core mechanistic claim that PERK is specifically required during the fetal/early-neonatal window for beta-cell proliferation and differentiation, and that its loss causes low beta-cell mass with proinsulin-trafficking failure, is established in tissue-specific mouse knockouts and PERK-deficient cell lines, not directly in human tissue. Human data are limited to genetics, a few functional kinase assays, and the pathologic observation that patient pancreata are hypoplastic with reduced beta cells. The human-tissue observation is consistent with the mouse mechanism but does not itself demonstrate the developmental-window requirement, which cannot be tested directly in humans.
Proposed experiments
Human iPSC-derived beta-cell developmental model of EIF2AK3 loss
wrs_ipsc_beta_cell_developmental_model
Differentiate EIF2AK3-null and isogenic-corrected human iPSCs along the pancreatic beta-cell lineage and quantify beta-cell yield, proinsulin handling, and endoplasmic reticulum stress across developmental stages to test whether the mouse developmental-window requirement holds in human cells.
Perturbations
EIF2AK3 knockout in human iPSC-derived beta cells
pathophysiology#ER-Stress-Induced Beta-Cell Failure
EIF2AK3 knockout versus isogenic correction in human iPSC-derived beta cells.
Readouts
Beta-cell mass and proinsulin trafficking
pathophysiology#ER-Stress-Induced Beta-Cell Failure
Direction: DECREASED
Interpretation: Reduced beta-cell yield and impaired proinsulin handling in the null line would support the developmental mechanism in human cells.
Show evidence (2 references)
PMID:17141632 SUPPORT Model Organism
"We discovered that PERK is specifically required in the insulin-secreting beta cells during the fetal and early neonatal period as a prerequisite for postnatal glucose homeostasis."
The mouse result whose translational fidelity to human WRS is the open question.
PMID:32321554 SUPPORT Human Clinical
"the pancreas of patients with WRS is hypoplastic, Langerhans islets are smaller and insulin-secreting beta cells are markedly reduced within the islets"
The human-tissue observation that is consistent with, but does not by itself demonstrate, the developmental-window mechanism.
Is a second locus responsible for the minority of clinically diagnosed WRS cases that lack an identifiable EIF2AK3 mutation?
KNOWLEDGE GAP wrs_genetic_heterogeneity
Attached to
genetic#EIF2AK3 Biallelic Loss of Function
In a functional study of 12 families, one patient had no EIF2AK3 involvement by both linkage and sequence data, and notably lacked the other variable manifestations of WRS, suggesting a distinct, uncharacterized genetic form. No second gene has been identified, so whether WRS is genetically heterogeneous remains open.
Show evidence (1 reference)
PMID:15220213 SUPPORT Human Clinical
"The patient with no EIF2AK3 involvement did not have any of the other variable clinical manifestations associated with WRS, which supports the idea that the genetic heterogeneity between this variant form of WRS and EIF2AK3 WRS correlates with some clinical heterogeneity."
The observation raising the possibility of genetic heterogeneity in WRS.
⚙

Pathophysiology

8
Biallelic EIF2AK3 Loss of Function
Both EIF2AK3 alleles carry loss-of-function variants (nonsense, frameshift, splice-site, or activity-abolishing missense), removing or inactivating PERK, a type I endoplasmic-reticulum transmembrane kinase. This is the initiating lesion; every downstream node in this entry is a consequence of PERK being unable to do its job.
EIF2AK3 hgnc:3255 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves EIF2AK3 (hgnc:3255). hgnc:3255 is a gene from the HUGO Gene Nomenclature Committee.
Genetic context EIF2AK3 hgnc:3255 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns EIF2AK3 (hgnc:3255). hgnc:3255 is a gene from the HUGO Gene Nomenclature Committee. variant_origin: GERMLINE zygosity: HOMOZYGOUS functional_impact_category: LOSS_OF_FUNCTION
Biallelic (usually homozygous in consanguineous kindreds) germline loss-of-function variants; disease-associated missense alleles abolish PERK kinase activity in functional assays.
eukaryotic translation initiation factor 2alpha kinase activity GO:0004694 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves eukaryotic translation initiation factor 2alpha kinase activity (GO:0004694), qualified as loss of function. GO:0004694 is a molecular function from the Gene Ontology. ⇓ LOSS OF FUNCTION
endoplasmic reticulum membrane GO:0005789 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves endoplasmic reticulum membrane (GO:0005789). GO:0005789 is a cellular component from the Gene Ontology.
Downstream
Failure of eIF2-alpha Phosphorylation and PERK-Branch UPR Loss of PERK kinase activity removes the ability to phosphorylate eIF2-alpha in response to endoplasmic reticulum stress.
Show evidence (2 references)
PMID:10932183 SUPPORT Human Clinical
"We identified distinct mutations of EIF2AK3 that segregated with the disorder in each of the families. The first mutation produces a truncated protein in which the entire catalytic domain is missing."
The gene-identification study establishing biallelic EIF2AK3 variants, including a catalytic-domain-truncating allele, as the cause of WRS.
PMID:15220213 SUPPORT Human Clinical
"The activities of missense versions of EIF2AK3 were characterized in vivo and in vitro and found to have a complete lack of activity in four mutant proteins and residual kinase activity in one."
Functional assays confirm that disease-associated missense variants abolish (or nearly abolish) PERK kinase activity, defining the loss-of-function mechanism.
Failure of eIF2-alpha Phosphorylation and PERK-Branch UPR
PERK normally phosphorylates eIF2-alpha at Ser51, attenuating cap-dependent translation and engaging the PERK arm of the unfolded protein response. Without functional PERK this translational brake is lost, so the cell cannot slow protein synthesis when misfolded protein accumulates in the endoplasmic reticulum. The parallel IRE1 and ATF6 arms cannot fully compensate.
PERK-mediated unfolded protein response GO:0036499 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves PERK-mediated unfolded protein response (GO:0036499), qualified as loss of function. GO:0036499 is a biological process from the Gene Ontology. ⇓ LOSS OF FUNCTION regulation of translational initiation GO:0006446 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased regulation of translational initiation (GO:0006446). GO:0006446 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Unresolved Endoplasmic Reticulum Stress Loss of the translational brake and the PERK-branch stress program leaves misfolded protein unbuffered in secretory cells.
Show evidence (1 reference)
PMID:21050479 SUPPORT Human Clinical
"PERK is an endoplasmic reticulum (ER) transmembrane protein, which plays a key role in translation control during the unfolded protein response. ER dysfunction is central to the disease processes."
The authoritative clinical review states PERK's role in translation control during the UPR and that ER dysfunction is central to WRS pathogenesis.
Unresolved Endoplasmic Reticulum Stress
Without the PERK-branch response, misfolded and unfolded protein accumulates in the endoplasmic reticulum of cells with high secretory or synthetic demand. This chronic, unbuffered endoplasmic reticulum stress is the shared cellular insult that branches to the pancreatic, hepatic, and skeletal phenotypes; it is a loss of adaptive reserve rather than a constant baseline organ failure, which is why hepatic injury in particular is episodic and stress-triggered.
response to endoplasmic reticulum stress GO:0034976 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased response to endoplasmic reticulum stress (GO:0034976). GO:0034976 is a biological process from the Gene Ontology. ↑ INCREASED
endoplasmic reticulum membrane GO:0005789 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves endoplasmic reticulum membrane (GO:0005789). GO:0005789 is a cellular component from the Gene Ontology.
Downstream
ER-Stress-Induced Beta-Cell Failure In pancreatic beta cells the unbuffered stress prevents normal development and drives apoptosis.
Stress-Triggered Hepatocyte Injury In hepatocytes, intercurrent illness raises the folding load past the cell's reduced reserve, triggering acute injury.
Impaired Skeletal Ossification and Bone Homeostasis In growth-plate chondrocytes and bone cells, loss of PERK impairs ossification and bone turnover.
Growth Retardation Loss of adaptive reserve across secretory and metabolic tissues contributes to the multisystem growth failure; the intervening steps are not resolved.
Renal Insufficiency Renal involvement is attributed to the same loss of stress-buffering capacity, but the tissue-specific mechanism is uncharacterized.
Global Developmental Delay Central nervous system involvement is ascribed to the same loss of adaptive capacity, with the intervening steps unresolved.
Neutropenia Insufficient hematopoiesis is attributed to the same mechanism, though its tissue-specific basis is not worked out.
Hypothyroidism Thyroid dysfunction is ascribed to the same loss of stress-buffering reserve, with uncharacterized intermediates.
Exocrine Pancreatic Insufficiency Exocrine pancreatic failure reflects the same loss of adaptive capacity in a high-secretory tissue; the intervening steps are not resolved.
Show evidence (1 reference)
PMID:25659842 SUPPORT Human Clinical
"Failure of appropriate PERK response results in accumulation of misfolded proteins, which leads to cell damage and apoptosis"
States the cellular mechanism linking failed PERK response to protein accumulation, cell damage, and apoptosis.
ER-Stress-Induced Beta-Cell Failure
PERK is specifically required during the fetal and early-neonatal window for beta-cell proliferation, differentiation, and proinsulin trafficking. PERK-null beta cells fail to expand, show low beta-cell mass and distended endoplasmic reticulum with retained proinsulin, and undergo apoptosis. In patients the pancreas is hypoplastic with small islets and markedly reduced beta cells. The developmental requirement is what makes the resulting diabetes permanent and very early in onset.
pancreatic beta cell CL:0000169 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves pancreatic beta cell, annotated with type B pancreatic cell (CL:0000169). CL:0000169 is a cell type from the Cell Ontology.
intrinsic apoptotic signaling in response to ER stress GO:0070059 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased intrinsic apoptotic signaling in response to ER stress, annotated with intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress (GO:0070059). GO:0070059 is a biological process from the Gene Ontology. ↑ INCREASED
Animal models
Perk (Eif2ak3) knockout mouse Mouse recapitulates Perk-null mice reproduce the developmental beta-cell failure that underlies the permanent neonatal diabetes.
Downstream
Insulin Deficiency Loss of beta-cell mass and function removes the source of endogenous insulin.
Show evidence (3 references)
PMID:17141632 SUPPORT Model Organism
"We discovered that PERK is specifically required in the insulin-secreting beta cells during the fetal and early neonatal period as a prerequisite for postnatal glucose homeostasis."
Tissue-specific mouse knockouts localize the developmental beta-cell requirement for PERK to the fetal/neonatal window, explaining permanence and early onset.
PMID:17141632 SUPPORT Model Organism
"We show that PERK-deficient mice exhibit severe defects in fetal/neonatal beta cell proliferation and differentiation, resulting in low beta cell mass, defects in proinsulin trafficking, and abrogation of insulin secretion that culminate in permanent neonatal diabetes."
Directly links PERK loss to reduced beta-cell mass, proinsulin-trafficking defects, and abolished insulin secretion in a mouse model of the human disease.
PMID:32321554 SUPPORT Human Clinical
"Consistently, the pancreas of patients with WRS is hypoplastic, Langerhans islets are smaller and insulin-secreting beta cells are markedly reduced within the islets"
Human pathology confirms the reduced beta-cell mass predicted by the mouse developmental mechanism.
Insulin Deficiency
Loss of beta-cell mass and impaired proinsulin handling collapse endogenous insulin secretion. The deficit is non-autoimmune, so islet autoantibodies are absent, distinguishing it from type 1 diabetes. It is the immediate mechanism producing the diabetes and the deficit that exogenous insulin replaces.
pancreatic beta cell CL:0000169 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves pancreatic beta cell, annotated with type B pancreatic cell (CL:0000169). CL:0000169 is a cell type from the Cell Ontology.
insulin secretion GO:0030073 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased insulin secretion (GO:0030073). GO:0030073 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Permanent Neonatal Diabetes Mellitus Insufficient endogenous insulin produces permanent insulin-dependent diabetes.
Show evidence (2 references)
PMID:20530744 SUPPORT Model Organism
"A substantial fraction of PERK-deficient beta-cells display a highly abnormal cellular phenotype characterized by grossly distended endoplasmic reticulum (ER) and retention of proinsulin."
Mechanistic mouse/cell study documenting the proinsulin-trafficking defect that contributes to the secretory failure behind insulin deficiency.
PMID:32321554 SUPPORT Human Clinical
"Diabetes in WRS is not autoimmune, therefore type 1 diabetes specific islet autoantibodies are absent"
Substantiates the non-autoimmune character and the absence of islet autoantibodies asserted in this node's description.
Stress-Triggered Hepatocyte Injury
At baseline hepatocytes tolerate PERK deficiency, but intercurrent illness or metabolic stress raises the folding and synthetic load past the reduced reserve, triggering acute hepatocyte injury. This is why hepatic disease presents as intermittent, virally triggered non-autoimmune hepatitis that can progress to acute hepatic failure, rather than as constant liver disease.
hepatocyte CL:0000182 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hepatocyte (CL:0000182). CL:0000182 is a cell type from the Cell Ontology.
liver UBERON:0002107 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in liver (UBERON:0002107). UBERON:0002107 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Recurrent Acute Hepatic Failure Repeated stress-triggered hepatocyte injury manifests clinically as recurrent acute hepatic failure.
Impaired Hepatic Gluconeogenesis Hepatocyte dysfunction impairs hepatic glucose production.
Show evidence (2 references)
PMID:25659842 SUPPORT Human Clinical
"The first presentation of liver disease in all 24 patients was acute non-autoimmune hepatitis triggered by viral illnesses and characterized by high liver enzymes, jaundice and hepatomegaly."
Directly documents the stress-triggered, intermittent, non-autoimmune hepatitis pattern in a genetically confirmed cohort.
PMID:32321554 SUPPORT Human Clinical
"The majority of individuals with WRS experience intermittent episodes of acute liver failure with or without cholestasis, typically triggered by stress such as intercurrent disease or hypoglycaemia related to tight diabetes control."
Confirms the episodic, stress-triggered character of the hepatic failure and names the triggers.
Impaired Hepatic Gluconeogenesis
Hepatic dysfunction impairs gluconeogenesis, so these patients lose a major counter-regulatory defense against hypoglycemia. This makes tight glycemic control dangerous, because hypoglycemia itself can precipitate hepatic decompensation.
liver UBERON:0002107 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in liver (UBERON:0002107). UBERON:0002107 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Hypoglycemia Loss of hepatic glucose output predisposes to recurrent hypoglycemia.
Show evidence (1 reference)
PMID:32321554 SUPPORT Human Clinical
"management of WRS is often complicated by recurrent episodes of hypoglycaemia secondary to liver dysfunction with impaired hepatic gluconeogenesis"
Directly links liver dysfunction and impaired hepatic gluconeogenesis to the recurrent hypoglycemia characteristic of WRS.
Impaired Skeletal Ossification and Bone Homeostasis
PERK loss impairs ossification and bone turnover in growth-plate chondrocytes and bone cells, producing the multiple epiphyseal or spondyloepiphyseal dysplasia, osteopenia, and fracture tendency of WRS, and extending to craniocervical structures (os odontoideum). Human genetic evidence confirms a role for EIF2AK3 in skeletal development; the cellular bone-homeostasis detail derives principally from Perk-knockout mouse models.
osteoblast CL:0000062 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves osteoblast (CL:0000062). CL:0000062 is a cell type from the Cell Ontology. osteoclast CL:0000092 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves osteoclast (CL:0000092). CL:0000092 is a cell type from the Cell Ontology.
Downstream
Multiple Epiphyseal Dysplasia Impaired epiphyseal ossification produces the multiple epiphyseal dysplasia.
Atlantoaxial Instability The same skeletal defect extends to the odontoid process, producing os odontoideum with atlantoaxial instability.
Osteoporosis Impaired bone turnover produces the osteoporosis and fracture tendency seen later in the disease course.
Show evidence (1 reference)
PMID:26860746 SUPPORT Human Clinical
"This additional evidence broadens the clinical spectrum of this syndrome and confirms the role of EIF2AK3 in skeletal development."
Human case series confirming a direct role for EIF2AK3 in skeletal development, including the craniocervical junction.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Wolcott-Rallison Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

12
Blood 1
Neutropenia FREQUENT Decreased total neutrophil count HP:0001875 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Decreased neutrophil count, annotated with Decreased total neutrophil count (HP:0001875). HP:0001875 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38230874 SUPPORT Human Clinical
"The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine..."
Systematic review quantifies insufficient haematopoiesis (including neutropenia) at 34.4%, within the FREQUENT band.
Digestive 2
Recurrent Acute Hepatic Failure FREQUENT HP:0006554 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Acute hepatic failure (HP:0006554), qualified as temporality recurrent. HP:0006554 is a phenotype from the Human Phenotype Ontology.
Temporal: RECURRENT
Show evidence (2 references)
PMID:25659842 SUPPORT Human Clinical
"22/24 had at least one episode of acute hepatic failure which was the cause of death in all deceased patients (13/28)."
Documents acute hepatic failure in the large majority of patients with liver disease and as the cause of death in all deceased patients.
PMID:21050479 SUPPORT Human Clinical
"Early diagnosis is recommended, in order to ensure rapid intervention for episodes of hepatic failure, which is the most life threatening complication."
Identifies hepatic failure as the most life-threatening complication of WRS.
Exocrine Pancreatic Insufficiency OCCASIONAL HP:0001738 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Exocrine pancreatic insufficiency (HP:0001738). HP:0001738 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38230874 SUPPORT Human Clinical
"The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine..."
Systematic review quantifies exocrine pancreatic insufficiency at 10.6%, within the OCCASIONAL band.
Endocrine 1
Hypothyroidism OCCASIONAL HP:0000821 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypothyroidism (HP:0000821). HP:0000821 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38230874 SUPPORT Human Clinical
"The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine..."
Systematic review quantifies hypothyroidism at 14.8%, within the OCCASIONAL band.
Genitourinary 1
Renal Insufficiency FREQUENT HP:0000083 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Renal insufficiency (HP:0000083). HP:0000083 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38230874 SUPPORT Human Clinical
"The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine..."
Systematic review quantifies renal involvement at 35.4%, within the FREQUENT band.
Metabolism 1
Hypoglycemia HP:0001943 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypoglycemia (HP:0001943). HP:0001943 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32321554 SUPPORT Human Clinical
"recurrent episodes of hypoglycaemia secondary to liver dysfunction with impaired hepatic gluconeogenesis"
Directly documents recurrent hypoglycemia secondary to impaired hepatic gluconeogenesis.
Musculoskeletal 3
Multiple Epiphyseal Dysplasia FREQUENT HP:0002656 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Multiple epiphyseal dysplasia, annotated with Epiphyseal dysplasia (HP:0002656). HP:0002656 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38230874 SUPPORT Human Clinical
"The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine..."
Systematic review of 159+ patients quantifies skeletal abnormalities at 59.8%, within the FREQUENT band.
Atlantoaxial Instability HP:0003467 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Atlantoaxial instability (HP:0003467). HP:0003467 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26860746 SUPPORT Human Clinical
"We report 4 children with WRS and Os Odontoideum resulting in significant neurological compromise."
Case series documenting os odontoideum with atlantoaxial instability and neurological compromise in WRS patients.
Osteoporosis HP:0000939 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteoporosis (HP:0000939). HP:0000939 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:10932183 SUPPORT Human Clinical
"Epiphyseal dysplasia, osteoporosis and growth retardation occur at a later age."
The gene-identification study lists osteoporosis as a later manifestation.
PMID:21050479 SUPPORT Human Clinical
"Bone fractures may be frequent."
The clinical review notes the frequent fractures that accompany the osteoporosis.
Nervous System 1
Global Developmental Delay FREQUENT HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38230874 SUPPORT Human Clinical
"The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine..."
Systematic review quantifies nervous-system involvement at 37.6%, within the FREQUENT band.
Growth 1
Growth Retardation FREQUENT Short stature HP:0004322 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short stature (HP:0004322). HP:0004322 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38230874 SUPPORT Human Clinical
"The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine..."
Systematic review quantifies impaired growth at 72%, within the FREQUENT band.
Other 1
Permanent Neonatal Diabetes Mellitus VERY_FREQUENT Neonatal insulin-dependent diabetes mellitus HP:0000857 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neonatal insulin-dependent diabetes mellitus (HP:0000857). HP:0000857 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:25659842 SUPPORT Human Clinical
"25/28 patients have PNDM (onset <6 months old; mean age at diagnosis 7.6 weeks)"
Establishes permanent neonatal diabetes as the presenting feature with a mean onset of 7.6 weeks in a genetically confirmed cohort.
PMID:21050479 SUPPORT Human Clinical
"Wolcott-Rallison syndrome (WRS) is a rare autosomal recessive disease, characterized by neonatal/early-onset non-autoimmune insulin-requiring diabetes associated with skeletal dysplasia and growth retardation."
The clinical review defines the diabetes as neonatal/early-onset, non-autoimmune, and insulin-requiring.
🧬

Genetic Associations

1
EIF2AK3 Biallelic Loss of Function
Gene: EIF2AK3 hgnc:3255 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is EIF2AK3 (hgnc:3255). hgnc:3255 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:15220213 SUPPORT Human Clinical
"With the exception of one case, all patients carried EIF2AK3 mutations resulting in truncated or missense versions of the protein."
Establishes EIF2AK3 truncating and missense variants as the cause across studied families, with rare exceptions.
PMID:10932183 SUPPORT Human Clinical
"The gene encoding the eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) resides in this interval"
The linkage-and-candidate-gene study that identified EIF2AK3 at the WRS locus.
💊

Medical Actions

5
Insulin Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: insulin CHEBI:145810 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses insulin (CHEBI:145810). CHEBI:145810 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Protein replacement
Lifelong insulin replacement, usually by continuous subcutaneous infusion (pump), is mandatory. Glycemic targets are deliberately relaxed because impaired hepatic gluconeogenesis makes these patients prone to hypoglycemia, which can itself trigger hepatic decompensation. Insulin replaces the missing hormone but does not slow beta-cell loss.
Mechanism Target:
RESTORES Insulin Deficiency — Exogenous insulin restores the hormone that the depleted beta-cell mass can no longer supply, without acting on the underlying cell loss.
Show evidence (1 reference)
PMID:32321554 SUPPORT Human Clinical
"At follow-up, 90% of patients were on insulin pump therapy"
Registry data documenting near-universal insulin pump therapy in WRS.
Liver or Multi-Organ Transplantation
Action: Organ TransplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Organ Transplantation (NCIT:C15289). NCIT:C15289 is a clinical intervention from the NCI Thesaurus. NCIT:C15289
Platform: Surgery
Liver transplantation, alone or combined with pancreas and/or kidney, is the single most impactful intervention demonstrated to date, significantly improving survival in patients with recurrent hepatic failure.
Mechanism Target:
INHIBITS Recurrent Acute Hepatic Failure — Replacing the failing liver removes the substrate for the recurrent, stress-triggered hepatic crises that drive mortality.
Show evidence (2 references)
PMID:38230874 SUPPORT Human Clinical
"Patient survival was significantly better in the transplant cohort (p = .0057)."
Systematic review showing a significant survival benefit for transplantation.
PMID:38230874 SUPPORT Human Clinical
"One-, five- and ten-year patient survival rates were 89.4%, 65.5% and 53.1%, respectively."
Provides the transplant-cohort survival rates supporting transplantation as a survival-improving option.
Multidisciplinary Supportive Care
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Platform: Other
There is no disease-modifying therapy. Care is supportive and multidisciplinary, centered on rapid, aggressive management of acute hepatic failure episodes (the dominant driver of mortality), treatment of hypothyroidism, renal dysfunction, and neutropenia/infection risk, orthopedic surveillance including screening for os odontoideum, and avoidance of unnecessary general anesthesia, whose hepatotoxicity can precipitate decompensation.
Show evidence (1 reference)
PMID:21050479 SUPPORT Human Clinical
"Interventions under general anaesthesia increase the risk of acute aggravation, because of the toxicity of anaesthetics, and should be avoided."
Documents the anesthesia-avoidance element of supportive care as a drug-safety consideration.
Genetic Counseling and Antenatal Diagnosis
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Platform: Behavioral / lifestyle
Because WRS is autosomal recessive with a 25% recurrence risk, genetic counseling and antenatal diagnosis are recommended for parents of an affected child once the familial EIF2AK3 mutation is known.
Show evidence (1 reference)
PMID:21050479 SUPPORT Human Clinical
"Genetic counselling and antenatal diagnosis is recommended for parents of a WRS patient with confirmed EIF2AK3 mutation."
States the genetic-counseling and antenatal-diagnosis recommendation.
Surgical Stabilization for Craniocervical Instability
Action: orthopedic surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is orthopedic surgical procedure (NCIT:C16186). NCIT:C16186 is a clinical intervention from the NCI Thesaurus. Ontology label: Orthopedic Surgical Procedure NCIT:C16186
Platform: Surgery
Symptomatic os odontoideum with atlantoaxial instability is managed by orthopedic/spinal surgical stabilization to prevent neurological and respiratory compromise, and active screening is recommended so it can be treated before irreversible injury.
Mechanism Target:
INHIBITS Atlantoaxial Instability — Surgical stabilization corrects the atlantoaxial instability and averts the neurological and respiratory compromise it would otherwise cause.
Show evidence (1 reference)
PMID:26860746 SUPPORT Human Clinical
"Os Odontoideum needs to be actively screened for in WRS patients to prevent neurological and respiratory compromise."
The case series motivates active screening and intervention for the instability to prevent neurological and respiratory compromise.
🌍

Environmental Factors

3
Intercurrent viral illness
intercurrent viral illness ECTO:3000001 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is intercurrent viral illness, annotated with exposure to virus (ECTO:3000001). ECTO:3000001 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Intercurrent viral (febrile) illness is the principal trigger of the acute hepatitis and hepatic-failure episodes, by raising the folding/synthetic load past the reduced PERK-dependent reserve of hepatocytes.
Show evidence (1 reference)
PMID:25659842 SUPPORT Human Clinical
"acute non-autoimmune hepatitis triggered by viral illnesses"
Establishes viral illness as the trigger of the hepatitis episodes in the cohort.
Mechanism Target:
TRIGGERS Stress-Triggered Hepatocyte Injury — Viral illness precipitates the acute non-autoimmune hepatitis that opens each hepatic crisis.
Show evidence (1 reference)
PMID:25659842 SUPPORT Human Clinical
"acute non-autoimmune hepatitis triggered by viral illnesses"
Directly attributes the first hepatitis presentation to viral-illness triggers.
General anaesthesia
general anaesthesia ECTO:2000059 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is general anaesthesia, annotated with exposure to anesthetics (ECTO:2000059). ECTO:2000059 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Interventions under general anaesthesia are an iatrogenic trigger of acute hepatic aggravation because of anaesthetic hepatotoxicity, and are advised against where avoidable.
Show evidence (1 reference)
PMID:21050479 SUPPORT Human Clinical
"Interventions under general anaesthesia increase the risk of acute aggravation, because of the toxicity of anaesthetics, and should be avoided."
Establishes general anaesthesia as a hepatotoxic aggravating exposure in WRS.
Mechanism Target:
TRIGGERS Stress-Triggered Hepatocyte Injury — Anaesthetic hepatotoxicity can precipitate acute hepatic aggravation on top of the reduced hepatocyte reserve.
Show evidence (1 reference)
PMID:21050479 SUPPORT Human Clinical
"Interventions under general anaesthesia increase the risk of acute aggravation, because of the toxicity of anaesthetics, and should be avoided."
Directly links general anaesthesia to acute aggravation via anaesthetic toxicity.
Iatrogenic hypoglycemia from tight glycemic control
iatrogenic hypoglycemia from tight glycemic control Relation: this environmental factor is this exposure This environmental factor is iatrogenic hypoglycemia from tight glycemic control.
Hypoglycemia related to tight diabetes control is an iatrogenic trigger of hepatic decompensation, compounded by the impaired hepatic gluconeogenesis of the disease.
Show evidence (1 reference)
PMID:32321554 SUPPORT Human Clinical
"typically triggered by stress such as intercurrent disease or hypoglycaemia related to tight diabetes control"
Establishes iatrogenic hypoglycemia as a trigger of hepatic decompensation.
Mechanism Target:
TRIGGERS Stress-Triggered Hepatocyte Injury — Hypoglycemia from tight diabetes control is listed among the stressors that precipitate the acute liver-failure episodes.
Show evidence (1 reference)
PMID:32321554 SUPPORT Human Clinical
"typically triggered by stress such as intercurrent disease or hypoglycaemia related to tight diabetes control"
Names hypoglycemia from tight diabetes control among the triggers of acute liver failure.
🔬

Diagnosis

1
Molecular genetic testing and autoantibody-negative diabetes
WRS should be suspected in any infant with permanent neonatal diabetes plus skeletal dysplasia and/or acute liver failure, especially with parental consanguinity; molecular genetic testing of EIF2AK3 confirms the diagnosis. Absence of type 1 diabetes islet autoantibodies distinguishes the non-autoimmune diabetes of WRS from autoimmune type 1 diabetes.
molecular genetic testing of EIF2AK3 NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:21050479 SUPPORT Human Clinical
"WRS should be suspected in any infant who presents with permanent neonatal diabetes associated with skeletal dysplasia and/or episodes of acute liver failure. Molecular genetic testing confirms the diagnosis."
Establishes the clinical suspicion criteria and molecular-genetic confirmation.
PMID:32321554 SUPPORT Human Clinical
"Diabetes in WRS is not autoimmune, therefore type 1 diabetes specific islet autoantibodies are absent"
Supports the autoantibody-negative discriminator versus autoimmune type 1 diabetes.
📈

Progression

2
Neonatal/early-infancy onset - diabetes
Permanent insulin-dependent diabetes presents first, before six months of age in the large majority (mean age at diagnosis about 7.6 weeks), often with diabetic ketoacidosis.
Show evidence (1 reference)
PMID:25659842 SUPPORT Human Clinical
"25/28 patients have PNDM (onset <6 months old; mean age at diagnosis 7.6 weeks)"
Gives the onset timing of the presenting diabetes.
Childhood - hepatic crises, skeletal dysplasia, high mortality
Skeletal dysplasia and recurrent stress-triggered hepatic failure emerge over the first years of life; hepatic failure is the leading cause of death, with a mean age at death around 5.8 years in the largest cohort. Missense genotype and liver/multi-organ transplantation are associated with longer survival.
Show evidence (2 references)
PMID:25659842 SUPPORT Human Clinical
"46.4% of patients were deceased (13/28) at a mean age of 5.8 years"
Gives the mortality rate and mean age at death.
PMID:38230874 SUPPORT Human Clinical
"Overall survival was better in individuals with missense mutations (p = .013)."
Establishes the genotype effect on survival in a large systematic review.
📊

Prevalence

2
Worldwide
Cases In Literature Ultra Rare
Fewer than 60 cases had been described at the time of the reference review; later systematic reviews assembled roughly 159-189 patients. True prevalence is unknown and likely underestimated. WRS is nonetheless the most frequent cause of neonatal/early-onset diabetes in consanguineous populations.
Show evidence (1 reference)
PMID:21050479 SUPPORT Human Clinical
"Fewer than 60 cases have been described in the literature, although WRS is now recognised as the most frequent cause of neonatal/early-onset diabetes in patients with consanguineous parents."
Gives the case-count and the epidemiologic significance among consanguineous populations.
Saudi Arabia
Cases In Literature Ultra Rare
Saudi Arabia accounted for 27.7% (23/83) of reported WRS patients worldwide as of 2013, and Saudi WRS patients represented 59% of all permanent neonatal diabetes cases attributable to WRS, illustrating the disproportionate burden in consanguineous populations.
Show evidence (1 reference)
PMID:23759358 SUPPORT Human Clinical
"All Saudi patients with WRS presented with PNDM, and they represent 59% of all PNDM cases from WRS."
Quantifies the share of WRS-attributable permanent neonatal diabetes arising in this consanguineous population.
🐁

Animal Models

1
Perk (Eif2ak3) knockout mouse
Global and tissue-specific Perk-knockout mice reproduce the permanent neonatal diabetes of WRS through failed fetal/neonatal beta-cell proliferation and differentiation with low beta-cell mass and proinsulin-trafficking defects. The pancreatic and skeletal phenotypes are the best-characterized; the episodic, infection-triggered hepatic failure that dominates the human natural history is not a prominent readout in the model.
Species
Mouse
Genotype
Eif2ak3 (Perk) knockout
Publication
PMID:17141632
Pathograph links
ER-Stress-Induced Beta-Cell Failure recapitulates fidelity: high Perk-null mice reproduce the developmental beta-cell failure that underlies the permanent neonatal diabetes.
Limitations: Species differences in beta-cell developmental timing, and the model does not reproduce the episodic, infection-triggered hepatic failure of human WRS.
Readouts
Beta-cell mass
Direction: DECREASED
Interpretation: Reduced beta-cell mass is the structural correlate of the beta-cell failure node.
Show evidence (1 reference)
PMID:17141632 SUPPORT Model Organism
"resulting in low beta cell mass, defects in proinsulin trafficking, and abrogation of insulin secretion that culminate in permanent neonatal diabetes"
Reports the reduced beta-cell mass measured in the knockout.
Show evidence (1 reference)
PMID:17141632 SUPPORT Model Organism
"these anomalies are mirrored in Perk knockout mice"
Establishes the Perk-knockout mouse as a model reproducing the WRS anomalies.
Show evidence (1 reference)
PMID:17141632 SUPPORT Model Organism
"Mutations in PERK (EIF2AK3) result in permanent neonatal diabetes as well as several other anomalies that underlie the human Wolcott-Rallison syndrome, and these anomalies are mirrored in Perk knockout mice."
States that the Perk-knockout mouse mirrors the anomalies of human WRS.
{ }

Source YAML

click to show 
name: Wolcott-Rallison Syndrome
creation_date: "2026-09-04T00:00:00Z"
category: Mendelian
parents:
- Monogenic Diabetes
disease_term:
  preferred_term: Wolcott-Rallison Syndrome
  term:
    id: MONDO:0009192
    label: Wolcott-Rallison syndrome
synonyms:
- WRS
- early-onset diabetes mellitus with multiple epiphyseal dysplasia
- epiphyseal dysplasia, multiple, with early-onset diabetes mellitus
- multiple epiphyseal dysplasia and early-onset diabetes mellitus
description: >-
  Wolcott-Rallison syndrome (WRS) is a rare autosomal recessive disorder caused
  by biallelic loss-of-function variants in EIF2AK3, which encodes the
  endoplasmic-reticulum transmembrane kinase PERK (PKR-like endoplasmic reticulum
  kinase). PERK phosphorylates the translation initiation factor eIF2-alpha to
  attenuate protein synthesis during the unfolded protein response; without it,
  cells with a high secretory or synthetic load cannot buffer endoplasmic
  reticulum stress and die by apoptosis. The pancreatic beta cell is the first
  and most consistently affected: PERK is required during fetal and early
  neonatal life for beta-cell expansion, differentiation, and proinsulin
  handling, so its loss produces permanent, non-autoimmune, insulin-dependent
  diabetes that presents before six months of age. The same loss of adaptive
  reserve produces multiple epiphyseal or spondyloepiphyseal dysplasia with
  growth retardation, and recurrent, stress-triggered episodes of acute hepatic
  failure that are the leading cause of death. Variable additional features
  include renal dysfunction, hypothyroidism, neutropenia with recurrent
  infections, exocrine pancreatic insufficiency, developmental delay, and
  craniocervical (os odontoideum) instability. WRS is now recognized as the most
  frequent cause of permanent neonatal diabetes in consanguineous populations.
  There is no disease-modifying therapy; management is insulin replacement,
  aggressive supportive treatment of hepatic crises, and liver or multi-organ
  transplantation, which improves survival.
pathophysiology:
- name: Biallelic EIF2AK3 Loss of Function
  biological_scale: MOLECULAR
  description: >-
    Both EIF2AK3 alleles carry loss-of-function variants (nonsense, frameshift,
    splice-site, or activity-abolishing missense), removing or inactivating PERK,
    a type I endoplasmic-reticulum transmembrane kinase. This is the initiating
    lesion; every downstream node in this entry is a consequence of PERK being
    unable to do its job.
  genes:
  - preferred_term: EIF2AK3
    term:
      id: hgnc:3255
      label: EIF2AK3
  genetic_context:
    genes:
    - preferred_term: EIF2AK3
      term:
        id: hgnc:3255
        label: EIF2AK3
    variant_origin: GERMLINE
    zygosity: HOMOZYGOUS
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      Biallelic (usually homozygous in consanguineous kindreds) germline
      loss-of-function variants; disease-associated missense alleles abolish PERK
      kinase activity in functional assays.
  molecular_functions:
  - preferred_term: eukaryotic translation initiation factor 2alpha kinase activity
    term:
      id: GO:0004694
      label: eukaryotic translation initiation factor 2alpha kinase activity
    modifier: LOSS_OF_FUNCTION
  cellular_components:
  - preferred_term: endoplasmic reticulum membrane
    term:
      id: GO:0005789
      label: endoplasmic reticulum membrane
  downstream:
  - target: Failure of eIF2-alpha Phosphorylation and PERK-Branch UPR
    description: >-
      Loss of PERK kinase activity removes the ability to phosphorylate eIF2-alpha
      in response to endoplasmic reticulum stress.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:10932183
    reference_title: "EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified distinct mutations of EIF2AK3 that segregated with the disorder in each of the families. The first mutation produces a truncated protein in which the entire catalytic domain is missing."
    explanation: >-
      The gene-identification study establishing biallelic EIF2AK3 variants,
      including a catalytic-domain-truncating allele, as the cause of WRS.
  - reference: PMID:15220213
    reference_title: "Wolcott-Rallison Syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The activities of missense versions of EIF2AK3 were characterized in vivo and in vitro and found to have a complete lack of activity in four mutant proteins and residual kinase activity in one."
    explanation: >-
      Functional assays confirm that disease-associated missense variants
      abolish (or nearly abolish) PERK kinase activity, defining the loss-of-function
      mechanism.
- name: Failure of eIF2-alpha Phosphorylation and PERK-Branch UPR
  biological_scale: MOLECULAR
  description: >-
    PERK normally phosphorylates eIF2-alpha at Ser51, attenuating cap-dependent
    translation and engaging the PERK arm of the unfolded protein response. Without
    functional PERK this translational brake is lost, so the cell cannot slow
    protein synthesis when misfolded protein accumulates in the endoplasmic
    reticulum. The parallel IRE1 and ATF6 arms cannot fully compensate.
  biological_processes:
  - preferred_term: PERK-mediated unfolded protein response
    term:
      id: GO:0036499
      label: PERK-mediated unfolded protein response
    modifier: LOSS_OF_FUNCTION
  - preferred_term: regulation of translational initiation
    term:
      id: GO:0006446
      label: regulation of translational initiation
    modifier: DECREASED
  downstream:
  - target: Unresolved Endoplasmic Reticulum Stress
    description: >-
      Loss of the translational brake and the PERK-branch stress program leaves
      misfolded protein unbuffered in secretory cells.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:21050479
    reference_title: Wolcott-Rallison syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PERK is an endoplasmic reticulum (ER) transmembrane protein, which plays a key role in translation control during the unfolded protein response. ER dysfunction is central to the disease processes."
    explanation: >-
      The authoritative clinical review states PERK's role in translation control
      during the UPR and that ER dysfunction is central to WRS pathogenesis.
- name: Unresolved Endoplasmic Reticulum Stress
  biological_scale: CELLULAR
  description: >-
    Without the PERK-branch response, misfolded and unfolded protein accumulates
    in the endoplasmic reticulum of cells with high secretory or synthetic demand.
    This chronic, unbuffered endoplasmic reticulum stress is the shared cellular
    insult that branches to the pancreatic, hepatic, and skeletal phenotypes; it
    is a loss of adaptive reserve rather than a constant baseline organ failure,
    which is why hepatic injury in particular is episodic and stress-triggered.
  biological_processes:
  - preferred_term: response to endoplasmic reticulum stress
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
    modifier: INCREASED
  cellular_components:
  - preferred_term: endoplasmic reticulum membrane
    term:
      id: GO:0005789
      label: endoplasmic reticulum membrane
  downstream:
  - target: ER-Stress-Induced Beta-Cell Failure
    description: >-
      In pancreatic beta cells the unbuffered stress prevents normal development
      and drives apoptosis.
    causal_link_type: DIRECT
  - target: Stress-Triggered Hepatocyte Injury
    description: >-
      In hepatocytes, intercurrent illness raises the folding load past the cell's
      reduced reserve, triggering acute injury.
    causal_link_type: DIRECT
  - target: Impaired Skeletal Ossification and Bone Homeostasis
    description: >-
      In growth-plate chondrocytes and bone cells, loss of PERK impairs ossification
      and bone turnover.
    causal_link_type: DIRECT
  - target: Growth Retardation
    description: >-
      Loss of adaptive reserve across secretory and metabolic tissues contributes to
      the multisystem growth failure; the intervening steps are not resolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Renal Insufficiency
    description: >-
      Renal involvement is attributed to the same loss of stress-buffering capacity,
      but the tissue-specific mechanism is uncharacterized.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Global Developmental Delay
    description: >-
      Central nervous system involvement is ascribed to the same loss of adaptive
      capacity, with the intervening steps unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Neutropenia
    description: >-
      Insufficient hematopoiesis is attributed to the same mechanism, though its
      tissue-specific basis is not worked out.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Hypothyroidism
    description: >-
      Thyroid dysfunction is ascribed to the same loss of stress-buffering reserve,
      with uncharacterized intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Exocrine Pancreatic Insufficiency
    description: >-
      Exocrine pancreatic failure reflects the same loss of adaptive capacity in a
      high-secretory tissue; the intervening steps are not resolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:25659842
    reference_title: "Liver disease and other comorbidities in Wolcott-Rallison syndrome: different phenotype and variable associations in a large cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Failure of appropriate PERK response results in accumulation of misfolded proteins, which leads to cell damage and apoptosis"
    explanation: >-
      States the cellular mechanism linking failed PERK response to protein
      accumulation, cell damage, and apoptosis.
- name: ER-Stress-Induced Beta-Cell Failure
  biological_scale: CELLULAR
  description: >-
    PERK is specifically required during the fetal and early-neonatal window for
    beta-cell proliferation, differentiation, and proinsulin trafficking. PERK-null
    beta cells fail to expand, show low beta-cell mass and distended endoplasmic
    reticulum with retained proinsulin, and undergo apoptosis. In patients the
    pancreas is hypoplastic with small islets and markedly reduced beta cells. The
    developmental requirement is what makes the resulting diabetes permanent and
    very early in onset.
  cell_types:
  - preferred_term: pancreatic beta cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: intrinsic apoptotic signaling in response to ER stress
    term:
      id: GO:0070059
      label: intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress
    modifier: INCREASED
  downstream:
  - target: Insulin Deficiency
    description: >-
      Loss of beta-cell mass and function removes the source of endogenous insulin.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:17141632
    reference_title: PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We discovered that PERK is specifically required in the insulin-secreting beta cells during the fetal and early neonatal period as a prerequisite for postnatal glucose homeostasis."
    explanation: >-
      Tissue-specific mouse knockouts localize the developmental beta-cell
      requirement for PERK to the fetal/neonatal window, explaining permanence and
      early onset.
  - reference: PMID:17141632
    reference_title: PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We show that PERK-deficient mice exhibit severe defects in fetal/neonatal beta cell proliferation and differentiation, resulting in low beta cell mass, defects in proinsulin trafficking, and abrogation of insulin secretion that culminate in permanent neonatal diabetes."
    explanation: >-
      Directly links PERK loss to reduced beta-cell mass, proinsulin-trafficking
      defects, and abolished insulin secretion in a mouse model of the human disease.
  - reference: PMID:32321554
    reference_title: "Diabetes management in Wolcott-Rallison syndrome: analysis from the German/Austrian DPV database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Consistently, the pancreas of patients with WRS is hypoplastic, Langerhans islets are smaller and insulin-secreting beta cells are markedly reduced within the islets"
    explanation: >-
      Human pathology confirms the reduced beta-cell mass predicted by the mouse
      developmental mechanism.
- name: Insulin Deficiency
  biological_scale: CELLULAR
  description: >-
    Loss of beta-cell mass and impaired proinsulin handling collapse endogenous
    insulin secretion. The deficit is non-autoimmune, so islet autoantibodies are
    absent, distinguishing it from type 1 diabetes. It is the immediate mechanism
    producing the diabetes and the deficit that exogenous insulin replaces.
  cell_types:
  - preferred_term: pancreatic beta cell
    term:
      id: CL:0000169
      label: type B pancreatic cell
  biological_processes:
  - preferred_term: insulin secretion
    term:
      id: GO:0030073
      label: insulin secretion
    modifier: DECREASED
  downstream:
  - target: Permanent Neonatal Diabetes Mellitus
    description: >-
      Insufficient endogenous insulin produces permanent insulin-dependent diabetes.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:20530744
    reference_title: PERK (EIF2AK3) regulates proinsulin trafficking and quality control in the secretory pathway.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "A substantial fraction of PERK-deficient beta-cells display a highly abnormal cellular phenotype characterized by grossly distended endoplasmic reticulum (ER) and retention of proinsulin."
    explanation: >-
      Mechanistic mouse/cell study documenting the proinsulin-trafficking defect
      that contributes to the secretory failure behind insulin deficiency.
  - reference: PMID:32321554
    reference_title: "Diabetes management in Wolcott-Rallison syndrome: analysis from the German/Austrian DPV database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diabetes in WRS is not autoimmune, therefore type 1 diabetes specific islet autoantibodies are absent"
    explanation: >-
      Substantiates the non-autoimmune character and the absence of islet
      autoantibodies asserted in this node's description.
- name: Stress-Triggered Hepatocyte Injury
  biological_scale: CELLULAR
  description: >-
    At baseline hepatocytes tolerate PERK deficiency, but intercurrent illness or
    metabolic stress raises the folding and synthetic load past the reduced reserve,
    triggering acute hepatocyte injury. This is why hepatic disease presents as
    intermittent, virally triggered non-autoimmune hepatitis that can progress to
    acute hepatic failure, rather than as constant liver disease.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Recurrent Acute Hepatic Failure
    description: >-
      Repeated stress-triggered hepatocyte injury manifests clinically as recurrent
      acute hepatic failure.
    causal_link_type: DIRECT
  - target: Impaired Hepatic Gluconeogenesis
    description: >-
      Hepatocyte dysfunction impairs hepatic glucose production.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:25659842
    reference_title: "Liver disease and other comorbidities in Wolcott-Rallison syndrome: different phenotype and variable associations in a large cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The first presentation of liver disease in all 24 patients was acute non-autoimmune hepatitis triggered by viral illnesses and characterized by high liver enzymes, jaundice and hepatomegaly."
    explanation: >-
      Directly documents the stress-triggered, intermittent, non-autoimmune
      hepatitis pattern in a genetically confirmed cohort.
  - reference: PMID:32321554
    reference_title: "Diabetes management in Wolcott-Rallison syndrome: analysis from the German/Austrian DPV database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The majority of individuals with WRS experience intermittent episodes of acute liver failure with or without cholestasis, typically triggered by stress such as intercurrent disease or hypoglycaemia related to tight diabetes control."
    explanation: >-
      Confirms the episodic, stress-triggered character of the hepatic failure and
      names the triggers.
- name: Impaired Hepatic Gluconeogenesis
  biological_scale: TISSUE
  description: >-
    Hepatic dysfunction impairs gluconeogenesis, so these patients lose a major
    counter-regulatory defense against hypoglycemia. This makes tight glycemic
    control dangerous, because hypoglycemia itself can precipitate hepatic
    decompensation.
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Hypoglycemia
    description: >-
      Loss of hepatic glucose output predisposes to recurrent hypoglycemia.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:32321554
    reference_title: "Diabetes management in Wolcott-Rallison syndrome: analysis from the German/Austrian DPV database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "management of WRS is often complicated by recurrent episodes of hypoglycaemia secondary to liver dysfunction with impaired hepatic gluconeogenesis"
    explanation: >-
      Directly links liver dysfunction and impaired hepatic gluconeogenesis to the
      recurrent hypoglycemia characteristic of WRS.
- name: Impaired Skeletal Ossification and Bone Homeostasis
  biological_scale: TISSUE
  description: >-
    PERK loss impairs ossification and bone turnover in growth-plate chondrocytes
    and bone cells, producing the multiple epiphyseal or spondyloepiphyseal
    dysplasia, osteopenia, and fracture tendency of WRS, and extending to
    craniocervical structures (os odontoideum). Human genetic evidence confirms
    a role for EIF2AK3 in skeletal development; the cellular bone-homeostasis
    detail derives principally from Perk-knockout mouse models.
  cell_types:
  - preferred_term: osteoblast
    term:
      id: CL:0000062
      label: osteoblast
  - preferred_term: osteoclast
    term:
      id: CL:0000092
      label: osteoclast
  downstream:
  - target: Multiple Epiphyseal Dysplasia
    description: >-
      Impaired epiphyseal ossification produces the multiple epiphyseal dysplasia.
    causal_link_type: DIRECT
  - target: Atlantoaxial Instability
    description: >-
      The same skeletal defect extends to the odontoid process, producing os
      odontoideum with atlantoaxial instability.
    causal_link_type: DIRECT
  - target: Osteoporosis
    description: >-
      Impaired bone turnover produces the osteoporosis and fracture tendency seen
      later in the disease course.
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:26860746
    reference_title: "Os odontoideum in wolcott-rallison syndrome: a case series of 4 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This additional evidence broadens the clinical spectrum of this syndrome and confirms the role of EIF2AK3 in skeletal development."
    explanation: >-
      Human case series confirming a direct role for EIF2AK3 in skeletal
      development, including the craniocervical junction.
phenotypes:
- name: Permanent Neonatal Diabetes Mellitus
  category: Endocrine
  description: >-
    Permanent, non-autoimmune, insulin-dependent diabetes is the presenting and
    universal feature, typically appearing before six months of age (mean age at
    diagnosis about 7.6 weeks in the largest cohort). It is the single highest-yield
    trigger for considering WRS in a consanguineous infant.
  phenotype_term:
    preferred_term: Neonatal insulin-dependent diabetes mellitus
    term:
      id: HP:0000857
      label: Neonatal insulin-dependent diabetes mellitus
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:25659842
    reference_title: "Liver disease and other comorbidities in Wolcott-Rallison syndrome: different phenotype and variable associations in a large cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "25/28 patients have PNDM (onset <6 months old; mean age at diagnosis 7.6 weeks)"
    explanation: >-
      Establishes permanent neonatal diabetes as the presenting feature with a mean
      onset of 7.6 weeks in a genetically confirmed cohort.
  - reference: PMID:21050479
    reference_title: Wolcott-Rallison syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Wolcott-Rallison syndrome (WRS) is a rare autosomal recessive disease, characterized by neonatal/early-onset non-autoimmune insulin-requiring diabetes associated with skeletal dysplasia and growth retardation."
    explanation: >-
      The clinical review defines the diabetes as neonatal/early-onset,
      non-autoimmune, and insulin-requiring.
- name: Multiple Epiphyseal Dysplasia
  category: Skeletal
  description: >-
    Multiple epiphyseal (and spondyloepiphyseal) dysplasia with osteopenia and
    fracture tendency, generally diagnosed within the first year or two of life
    and progressive over childhood. Its reported frequency varies because subtle
    changes may be missed in young patients without regular skeletal surveys.
  phenotype_term:
    preferred_term: Multiple epiphyseal dysplasia
    term:
      id: HP:0002656
      label: Epiphyseal dysplasia
  frequency: FREQUENT
  evidence:
  - reference: PMID:38230874
    reference_title: "Natural history of Wolcott-Rallison syndrome: A systematic review and follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine pancreas insufficiency in 10.6%."
    explanation: >-
      Systematic review of 159+ patients quantifies skeletal abnormalities at
      59.8%, within the FREQUENT band.
- name: Recurrent Acute Hepatic Failure
  category: Hepatic
  description: >-
    Recurrent, stress-triggered episodes of acute hepatic failure, presenting as
    non-autoimmune hepatitis with markedly elevated transaminases, jaundice, and
    hepatomegaly. This is the most life-threatening manifestation and the leading
    cause of death.
  phenotype_term:
    preferred_term: Acute hepatic failure
    term:
      id: HP:0006554
      label: Acute hepatic failure
    temporality: RECURRENT
  frequency: FREQUENT
  evidence:
  - reference: PMID:25659842
    reference_title: "Liver disease and other comorbidities in Wolcott-Rallison syndrome: different phenotype and variable associations in a large cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "22/24 had at least one episode of acute hepatic failure which was the cause of death in all deceased patients (13/28)."
    explanation: >-
      Documents acute hepatic failure in the large majority of patients with liver
      disease and as the cause of death in all deceased patients.
  - reference: PMID:21050479
    reference_title: Wolcott-Rallison syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early diagnosis is recommended, in order to ensure rapid intervention for episodes of hepatic failure, which is the most life threatening complication."
    explanation: >-
      Identifies hepatic failure as the most life-threatening complication of WRS.
- name: Growth Retardation
  category: Growth
  description: >-
    Impaired linear growth and short stature are common, reflecting the combined
    endocrine, skeletal, and multisystem burden of the disease.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  frequency: FREQUENT
  evidence:
  - reference: PMID:38230874
    reference_title: "Natural history of Wolcott-Rallison syndrome: A systematic review and follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine pancreas insufficiency in 10.6%."
    explanation: >-
      Systematic review quantifies impaired growth at 72%, within the FREQUENT band.
- name: Renal Insufficiency
  category: Renal
  description: >-
    Renal dysfunction occurs in about a third of patients, often temporally
    associated with hepatic crises.
  phenotype_term:
    preferred_term: Renal insufficiency
    term:
      id: HP:0000083
      label: Renal insufficiency
  frequency: FREQUENT
  evidence:
  - reference: PMID:38230874
    reference_title: "Natural history of Wolcott-Rallison syndrome: A systematic review and follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine pancreas insufficiency in 10.6%."
    explanation: >-
      Systematic review quantifies renal involvement at 35.4%, within the FREQUENT band.
- name: Global Developmental Delay
  category: Neurologic
  description: >-
    Central nervous system involvement, including developmental delay and
    intellectual disability, is reported in over a third of patients.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  frequency: FREQUENT
  evidence:
  - reference: PMID:38230874
    reference_title: "Natural history of Wolcott-Rallison syndrome: A systematic review and follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine pancreas insufficiency in 10.6%."
    explanation: >-
      Systematic review quantifies nervous-system involvement at 37.6%, within the
      FREQUENT band.
- name: Neutropenia
  category: Hematologic
  description: >-
    Insufficient hematopoiesis, including neutropenia with recurrent infections and
    anemia, occurs in about a third of patients.
  phenotype_term:
    preferred_term: Decreased neutrophil count
    term:
      id: HP:0001875
      label: Decreased total neutrophil count
  frequency: FREQUENT
  evidence:
  - reference: PMID:38230874
    reference_title: "Natural history of Wolcott-Rallison syndrome: A systematic review and follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine pancreas insufficiency in 10.6%."
    explanation: >-
      Systematic review quantifies insufficient haematopoiesis (including
      neutropenia) at 34.4%, within the FREQUENT band.
- name: Hypothyroidism
  category: Endocrine
  description: >-
    Hypothyroidism, central and primary forms, is now recognized as a genuine WRS
    feature rather than an incidental finding, present in roughly one in seven
    patients.
  phenotype_term:
    preferred_term: Hypothyroidism
    term:
      id: HP:0000821
      label: Hypothyroidism
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:38230874
    reference_title: "Natural history of Wolcott-Rallison syndrome: A systematic review and follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine pancreas insufficiency in 10.6%."
    explanation: >-
      Systematic review quantifies hypothyroidism at 14.8%, within the OCCASIONAL band.
- name: Hypoglycemia
  category: Endocrine
  description: >-
    Recurrent hypoglycemia occurs secondary to hepatic dysfunction with impaired
    gluconeogenesis, and is worsened by tight glycemic control. It is an important
    management hazard because hypoglycemia can itself trigger hepatic decompensation.
  phenotype_term:
    preferred_term: Hypoglycemia
    term:
      id: HP:0001943
      label: Hypoglycemia
  evidence:
  - reference: PMID:32321554
    reference_title: "Diabetes management in Wolcott-Rallison syndrome: analysis from the German/Austrian DPV database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "recurrent episodes of hypoglycaemia secondary to liver dysfunction with impaired hepatic gluconeogenesis"
    explanation: >-
      Directly documents recurrent hypoglycemia secondary to impaired hepatic
      gluconeogenesis.
- name: Atlantoaxial Instability
  category: Skeletal
  description: >-
    Os odontoideum with atlantoaxial instability was identified as a WRS-associated
    finding causing significant neurological compromise, and should be actively
    screened for to prevent neurological and respiratory sequelae.
  phenotype_term:
    preferred_term: Atlantoaxial instability
    term:
      id: HP:0003467
      label: Atlantoaxial instability
  evidence:
  - reference: PMID:26860746
    reference_title: "Os odontoideum in wolcott-rallison syndrome: a case series of 4 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 4 children with WRS and Os Odontoideum resulting in significant neurological compromise."
    explanation: >-
      Case series documenting os odontoideum with atlantoaxial instability and
      neurological compromise in WRS patients.
- name: Exocrine Pancreatic Insufficiency
  category: Gastrointestinal
  description: >-
    Exocrine pancreatic insufficiency, reflecting involvement of the exocrine as
    well as the endocrine pancreas, is reported in about one in ten patients.
  phenotype_term:
    preferred_term: Exocrine pancreatic insufficiency
    term:
      id: HP:0001738
      label: Exocrine pancreatic insufficiency
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:38230874
    reference_title: "Natural history of Wolcott-Rallison syndrome: A systematic review and follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent clinical feature was neonatal diabetes in all patients, followed by liver impairment in 73%, impaired growth in 72%, skeletal abnormalities in 59.8%, the nervous system in 37.6%, the kidney in 35.4%, insufficient haematopoiesis in 34.4%, hypothyroidism in 14.8% and exocrine pancreas insufficiency in 10.6%."
    explanation: >-
      Systematic review quantifies exocrine pancreatic insufficiency at 10.6%, within
      the OCCASIONAL band.
- name: Osteoporosis
  category: Skeletal
  description: >-
    Osteoporosis with a tendency to bone fractures develops later in the disease
    course, alongside the epiphyseal dysplasia.
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:10932183
    reference_title: "EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epiphyseal dysplasia, osteoporosis and growth retardation occur at a later age."
    explanation: >-
      The gene-identification study lists osteoporosis as a later manifestation.
  - reference: PMID:21050479
    reference_title: Wolcott-Rallison syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bone fractures may be frequent."
    explanation: >-
      The clinical review notes the frequent fractures that accompany the
      osteoporosis.
genetic:
- name: EIF2AK3 Biallelic Loss of Function
  gene_term:
    preferred_term: EIF2AK3
    term:
      id: hgnc:3255
      label: EIF2AK3
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  features: >-
    EIF2AK3 (chromosome 2p11.2) encodes PERK. WRS is caused by biallelic
    (homozygous or compound heterozygous) loss-of-function variants; the majority
    are truncating (nonsense, frameshift, splice-site), with a substantial minority
    of activity-abolishing missense variants. Recurrent alleles arise within
    consanguineous kindreds rather than as a panethnic founder mutation. A minority
    of clinically diagnosed WRS cases lack an identifiable EIF2AK3 mutation,
    suggesting possible genetic heterogeneity.
  frequency: OBLIGATE
  evidence:
  - reference: PMID:15220213
    reference_title: "Wolcott-Rallison Syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "With the exception of one case, all patients carried EIF2AK3 mutations resulting in truncated or missense versions of the protein."
    explanation: >-
      Establishes EIF2AK3 truncating and missense variants as the cause across
      studied families, with rare exceptions.
  - reference: PMID:10932183
    reference_title: "EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The gene encoding the eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) resides in this interval"
    explanation: >-
      The linkage-and-candidate-gene study that identified EIF2AK3 at the WRS locus.
inheritance:
- name: Autosomal Recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    WRS is autosomal recessive with a 25% recurrence risk for future siblings;
    heterozygous carrier parents are clinically unaffected. Consanguinity is the
    dominant driver of case load, and the disorder is the most frequent cause of
    permanent neonatal diabetes in consanguineous populations.
  evidence:
  - reference: PMID:23759358
    reference_title: "Frequency and spectrum of Wolcott-Rallison syndrome in Saudi Arabia: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Wolcott-Rallison syndrome (WRS) is caused by recessive EIF2AK3 gene mutations and characterized by permanent neonatal diabetes (PNDM), skeletal dysplasia, and recurrent hepatitis."
    explanation: >-
      States the recessive inheritance and the defining triad.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Fewer than 60 cases had been described at the time of the reference review;
    later systematic reviews assembled roughly 159-189 patients. True prevalence is
    unknown and likely underestimated. WRS is nonetheless the most frequent cause of
    neonatal/early-onset diabetes in consanguineous populations.
  evidence:
  - reference: PMID:21050479
    reference_title: Wolcott-Rallison syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fewer than 60 cases have been described in the literature, although WRS is now recognised as the most frequent cause of neonatal/early-onset diabetes in patients with consanguineous parents."
    explanation: >-
      Gives the case-count and the epidemiologic significance among consanguineous
      populations.
- population: Saudi Arabia
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Saudi Arabia accounted for 27.7% (23/83) of reported WRS patients worldwide as
    of 2013, and Saudi WRS patients represented 59% of all permanent neonatal
    diabetes cases attributable to WRS, illustrating the disproportionate burden in
    consanguineous populations.
  evidence:
  - reference: PMID:23759358
    reference_title: "Frequency and spectrum of Wolcott-Rallison syndrome in Saudi Arabia: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All Saudi patients with WRS presented with PNDM, and they represent 59% of all PNDM cases from WRS."
    explanation: >-
      Quantifies the share of WRS-attributable permanent neonatal diabetes arising
      in this consanguineous population.
progression:
- phase: Neonatal/early-infancy onset - diabetes
  notes: >-
    Permanent insulin-dependent diabetes presents first, before six months of age
    in the large majority (mean age at diagnosis about 7.6 weeks), often with
    diabetic ketoacidosis.
  evidence:
  - reference: PMID:25659842
    reference_title: "Liver disease and other comorbidities in Wolcott-Rallison syndrome: different phenotype and variable associations in a large cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "25/28 patients have PNDM (onset <6 months old; mean age at diagnosis 7.6 weeks)"
    explanation: >-
      Gives the onset timing of the presenting diabetes.
- phase: Childhood - hepatic crises, skeletal dysplasia, high mortality
  notes: >-
    Skeletal dysplasia and recurrent stress-triggered hepatic failure emerge over
    the first years of life; hepatic failure is the leading cause of death, with a
    mean age at death around 5.8 years in the largest cohort. Missense genotype and
    liver/multi-organ transplantation are associated with longer survival.
  evidence:
  - reference: PMID:25659842
    reference_title: "Liver disease and other comorbidities in Wolcott-Rallison syndrome: different phenotype and variable associations in a large cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "46.4% of patients were deceased (13/28) at a mean age of 5.8 years"
    explanation: >-
      Gives the mortality rate and mean age at death.
  - reference: PMID:38230874
    reference_title: "Natural history of Wolcott-Rallison syndrome: A systematic review and follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall survival was better in individuals with missense mutations (p = .013)."
    explanation: >-
      Establishes the genotype effect on survival in a large systematic review.
treatments:
- name: Insulin Therapy
  description: >-
    Lifelong insulin replacement, usually by continuous subcutaneous infusion
    (pump), is mandatory. Glycemic targets are deliberately relaxed because
    impaired hepatic gluconeogenesis makes these patients prone to hypoglycemia,
    which can itself trigger hepatic decompensation. Insulin replaces the missing
    hormone but does not slow beta-cell loss.
  therapeutic_modality: PROTEIN_REPLACEMENT
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: insulin
      term:
        id: CHEBI:145810
        label: insulin
  target_mechanisms:
  - target: Insulin Deficiency
    treatment_effect: RESTORES
    description: >-
      Exogenous insulin restores the hormone that the depleted beta-cell mass can
      no longer supply, without acting on the underlying cell loss.
  evidence:
  - reference: PMID:32321554
    reference_title: "Diabetes management in Wolcott-Rallison syndrome: analysis from the German/Austrian DPV database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At follow-up, 90% of patients were on insulin pump therapy"
    explanation: >-
      Registry data documenting near-universal insulin pump therapy in WRS.
- name: Liver or Multi-Organ Transplantation
  description: >-
    Liver transplantation, alone or combined with pancreas and/or kidney, is the
    single most impactful intervention demonstrated to date, significantly improving
    survival in patients with recurrent hepatic failure.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Organ Transplantation
    term:
      id: NCIT:C15289
      label: Organ Transplantation
  target_mechanisms:
  - target: Recurrent Acute Hepatic Failure
    treatment_effect: INHIBITS
    description: >-
      Replacing the failing liver removes the substrate for the recurrent,
      stress-triggered hepatic crises that drive mortality.
  evidence:
  - reference: PMID:38230874
    reference_title: "Natural history of Wolcott-Rallison syndrome: A systematic review and follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patient survival was significantly better in the transplant cohort (p = .0057)."
    explanation: >-
      Systematic review showing a significant survival benefit for transplantation.
  - reference: PMID:38230874
    reference_title: "Natural history of Wolcott-Rallison syndrome: A systematic review and follow-up study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "One-, five- and ten-year patient survival rates were 89.4%, 65.5% and 53.1%, respectively."
    explanation: >-
      Provides the transplant-cohort survival rates supporting transplantation as a
      survival-improving option.
- name: Multidisciplinary Supportive Care
  description: >-
    There is no disease-modifying therapy. Care is supportive and multidisciplinary,
    centered on rapid, aggressive management of acute hepatic failure episodes (the
    dominant driver of mortality), treatment of hypothyroidism, renal dysfunction,
    and neutropenia/infection risk, orthopedic surveillance including screening for
    os odontoideum, and avoidance of unnecessary general anesthesia, whose
    hepatotoxicity can precipitate decompensation.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:21050479
    reference_title: Wolcott-Rallison syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Interventions under general anaesthesia increase the risk of acute aggravation, because of the toxicity of anaesthetics, and should be avoided."
    explanation: >-
      Documents the anesthesia-avoidance element of supportive care as a
      drug-safety consideration.
- name: Genetic Counseling and Antenatal Diagnosis
  description: >-
    Because WRS is autosomal recessive with a 25% recurrence risk, genetic
    counseling and antenatal diagnosis are recommended for parents of an affected
    child once the familial EIF2AK3 mutation is known.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:21050479
    reference_title: Wolcott-Rallison syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic counselling and antenatal diagnosis is recommended for parents of a WRS patient with confirmed EIF2AK3 mutation."
    explanation: >-
      States the genetic-counseling and antenatal-diagnosis recommendation.
- name: Surgical Stabilization for Craniocervical Instability
  description: >-
    Symptomatic os odontoideum with atlantoaxial instability is managed by
    orthopedic/spinal surgical stabilization to prevent neurological and
    respiratory compromise, and active screening is recommended so it can be
    treated before irreversible injury.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: orthopedic surgical procedure
    term:
      id: NCIT:C16186
      label: Orthopedic Surgical Procedure
  target_mechanisms:
  - target: Atlantoaxial Instability
    treatment_effect: INHIBITS
    description: >-
      Surgical stabilization corrects the atlantoaxial instability and averts the
      neurological and respiratory compromise it would otherwise cause.
  evidence:
  - reference: PMID:26860746
    reference_title: "Os odontoideum in wolcott-rallison syndrome: a case series of 4 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Os Odontoideum needs to be actively screened for in WRS patients to prevent neurological and respiratory compromise."
    explanation: >-
      The case series motivates active screening and intervention for the
      instability to prevent neurological and respiratory compromise.
environmental:
- name: Intercurrent viral illness
  description: >-
    Intercurrent viral (febrile) illness is the principal trigger of the acute
    hepatitis and hepatic-failure episodes, by raising the folding/synthetic load
    past the reduced PERK-dependent reserve of hepatocytes.
  exposure_term:
    preferred_term: intercurrent viral illness
    term:
      id: ECTO:3000001
      label: exposure to virus
  influences_mechanisms:
  - target: Stress-Triggered Hepatocyte Injury
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Viral illness precipitates the acute non-autoimmune hepatitis that opens each
      hepatic crisis.
    evidence:
    - reference: PMID:25659842
      reference_title: "Liver disease and other comorbidities in Wolcott-Rallison syndrome: different phenotype and variable associations in a large cohort."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "acute non-autoimmune hepatitis triggered by viral illnesses"
      explanation: >-
        Directly attributes the first hepatitis presentation to viral-illness triggers.
  evidence:
  - reference: PMID:25659842
    reference_title: "Liver disease and other comorbidities in Wolcott-Rallison syndrome: different phenotype and variable associations in a large cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "acute non-autoimmune hepatitis triggered by viral illnesses"
    explanation: >-
      Establishes viral illness as the trigger of the hepatitis episodes in the cohort.
- name: General anaesthesia
  description: >-
    Interventions under general anaesthesia are an iatrogenic trigger of acute
    hepatic aggravation because of anaesthetic hepatotoxicity, and are advised
    against where avoidable.
  exposure_term:
    preferred_term: general anaesthesia
    term:
      id: ECTO:2000059
      label: exposure to anesthetics
  influences_mechanisms:
  - target: Stress-Triggered Hepatocyte Injury
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Anaesthetic hepatotoxicity can precipitate acute hepatic aggravation on top of
      the reduced hepatocyte reserve.
    evidence:
    - reference: PMID:21050479
      reference_title: Wolcott-Rallison syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Interventions under general anaesthesia increase the risk of acute aggravation, because of the toxicity of anaesthetics, and should be avoided."
      explanation: >-
        Directly links general anaesthesia to acute aggravation via anaesthetic toxicity.
  evidence:
  - reference: PMID:21050479
    reference_title: Wolcott-Rallison syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Interventions under general anaesthesia increase the risk of acute aggravation, because of the toxicity of anaesthetics, and should be avoided."
    explanation: >-
      Establishes general anaesthesia as a hepatotoxic aggravating exposure in WRS.
- name: Iatrogenic hypoglycemia from tight glycemic control
  description: >-
    Hypoglycemia related to tight diabetes control is an iatrogenic trigger of
    hepatic decompensation, compounded by the impaired hepatic gluconeogenesis of
    the disease.
  exposure_term:
    preferred_term: iatrogenic hypoglycemia from tight glycemic control
  review_notes: >-
    Exposure term left unbound: ECTO was searched (exposure-to terms, anaesthetics,
    virus, hypoglycaemia) and carries no term for iatrogenic hypoglycemia or tight
    glycemic control, so preferred_term is free text per the environmental-term rules.
  influences_mechanisms:
  - target: Stress-Triggered Hepatocyte Injury
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Hypoglycemia from tight diabetes control is listed among the stressors that
      precipitate the acute liver-failure episodes.
    evidence:
    - reference: PMID:32321554
      reference_title: "Diabetes management in Wolcott-Rallison syndrome: analysis from the German/Austrian DPV database."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "typically triggered by stress such as intercurrent disease or hypoglycaemia related to tight diabetes control"
      explanation: >-
        Names hypoglycemia from tight diabetes control among the triggers of acute
        liver failure.
  evidence:
  - reference: PMID:32321554
    reference_title: "Diabetes management in Wolcott-Rallison syndrome: analysis from the German/Austrian DPV database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "typically triggered by stress such as intercurrent disease or hypoglycaemia related to tight diabetes control"
    explanation: >-
      Establishes iatrogenic hypoglycemia as a trigger of hepatic decompensation.
animal_models:
- name: Perk (Eif2ak3) knockout mouse
  species: Mouse
  genotype: Eif2ak3 (Perk) knockout
  publication: PMID:17141632
  description: >-
    Global and tissue-specific Perk-knockout mice reproduce the permanent neonatal
    diabetes of WRS through failed fetal/neonatal beta-cell proliferation and
    differentiation with low beta-cell mass and proinsulin-trafficking defects. The
    pancreatic and skeletal phenotypes are the best-characterized; the episodic,
    infection-triggered hepatic failure that dominates the human natural history is
    not a prominent readout in the model.
  modeled_mechanisms:
  - target: ER-Stress-Induced Beta-Cell Failure
    relationship: RECAPITULATES
    fidelity: HIGH
    model_scale: CELLULAR
    description: >-
      Perk-null mice reproduce the developmental beta-cell failure that underlies the
      permanent neonatal diabetes.
    limitations: >-
      Species differences in beta-cell developmental timing, and the model does not
      reproduce the episodic, infection-triggered hepatic failure of human WRS.
    readouts:
    - name: Beta-cell mass
      target: ER-Stress-Induced Beta-Cell Failure
      direction: DECREASED
      interpretation: >-
        Reduced beta-cell mass is the structural correlate of the beta-cell failure node.
      evidence:
      - reference: PMID:17141632
        reference_title: PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "resulting in low beta cell mass, defects in proinsulin trafficking, and abrogation of insulin secretion that culminate in permanent neonatal diabetes"
        explanation: Reports the reduced beta-cell mass measured in the knockout.
    evidence:
    - reference: PMID:17141632
      reference_title: PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "these anomalies are mirrored in Perk knockout mice"
      explanation: >-
        Establishes the Perk-knockout mouse as a model reproducing the WRS anomalies.
  evidence:
  - reference: PMID:17141632
    reference_title: PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Mutations in PERK (EIF2AK3) result in permanent neonatal diabetes as well as several other anomalies that underlie the human Wolcott-Rallison syndrome, and these anomalies are mirrored in Perk knockout mice."
    explanation: >-
      States that the Perk-knockout mouse mirrors the anomalies of human WRS.
diagnosis:
- name: Molecular genetic testing and autoantibody-negative diabetes
  diagnosis_term:
    preferred_term: molecular genetic testing of EIF2AK3
    term:
      id: NCIT:C15709
      label: Genetic Testing
  description: >-
    WRS should be suspected in any infant with permanent neonatal diabetes plus
    skeletal dysplasia and/or acute liver failure, especially with parental
    consanguinity; molecular genetic testing of EIF2AK3 confirms the diagnosis.
    Absence of type 1 diabetes islet autoantibodies distinguishes the non-autoimmune
    diabetes of WRS from autoimmune type 1 diabetes.
  evidence:
  - reference: PMID:21050479
    reference_title: Wolcott-Rallison syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "WRS should be suspected in any infant who presents with permanent neonatal diabetes associated with skeletal dysplasia and/or episodes of acute liver failure. Molecular genetic testing confirms the diagnosis."
    explanation: >-
      Establishes the clinical suspicion criteria and molecular-genetic confirmation.
  - reference: PMID:32321554
    reference_title: "Diabetes management in Wolcott-Rallison syndrome: analysis from the German/Austrian DPV database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diabetes in WRS is not autoimmune, therefore type 1 diabetes specific islet autoantibodies are absent"
    explanation: >-
      Supports the autoantibody-negative discriminator versus autoimmune type 1 diabetes.
references:
- reference: PMID:21050479
  title: Wolcott-Rallison syndrome.
discussions:
- discussion_id: wrs_beta_cell_developmental_mechanism_human_fidelity
  kind: HUMAN_MODEL_MISMATCH
  prompt: >-
    Is the fetal/neonatal beta-cell developmental requirement for PERK, demonstrated
    in Perk-knockout mice, the operative mechanism of the permanent diabetes in
    human WRS?
  attaches_to:
  - pathophysiology#ER-Stress-Induced Beta-Cell Failure
  rationale: >-
    The core mechanistic claim that PERK is specifically required during the
    fetal/early-neonatal window for beta-cell proliferation and differentiation, and
    that its loss causes low beta-cell mass with proinsulin-trafficking failure, is
    established in tissue-specific mouse knockouts and PERK-deficient cell lines,
    not directly in human tissue. Human data are limited to genetics, a few
    functional kinase assays, and the pathologic observation that patient pancreata
    are hypoplastic with reduced beta cells. The human-tissue observation is
    consistent with the mouse mechanism but does not itself demonstrate the
    developmental-window requirement, which cannot be tested directly in humans.
  proposed_experiments:
  - experiment_id: wrs_ipsc_beta_cell_developmental_model
    name: Human iPSC-derived beta-cell developmental model of EIF2AK3 loss
    description: >-
      Differentiate EIF2AK3-null and isogenic-corrected human iPSCs along the
      pancreatic beta-cell lineage and quantify beta-cell yield, proinsulin
      handling, and endoplasmic reticulum stress across developmental stages to test
      whether the mouse developmental-window requirement holds in human cells.
    perturbations:
    - name: EIF2AK3 knockout in human iPSC-derived beta cells
      target: pathophysiology#ER-Stress-Induced Beta-Cell Failure
      description: EIF2AK3 knockout versus isogenic correction in human iPSC-derived beta cells.
    readouts:
    - name: Beta-cell mass and proinsulin trafficking
      target: pathophysiology#ER-Stress-Induced Beta-Cell Failure
      direction: DECREASED
      interpretation: >-
        Reduced beta-cell yield and impaired proinsulin handling in the null line
        would support the developmental mechanism in human cells.
  evidence:
  - reference: PMID:17141632
    reference_title: PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We discovered that PERK is specifically required in the insulin-secreting beta cells during the fetal and early neonatal period as a prerequisite for postnatal glucose homeostasis."
    explanation: >-
      The mouse result whose translational fidelity to human WRS is the open question.
  - reference: PMID:32321554
    reference_title: "Diabetes management in Wolcott-Rallison syndrome: analysis from the German/Austrian DPV database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the pancreas of patients with WRS is hypoplastic, Langerhans islets are smaller and insulin-secreting beta cells are markedly reduced within the islets"
    explanation: >-
      The human-tissue observation that is consistent with, but does not by itself
      demonstrate, the developmental-window mechanism.
- discussion_id: wrs_genetic_heterogeneity
  kind: KNOWLEDGE_GAP
  prompt: >-
    Is a second locus responsible for the minority of clinically diagnosed WRS
    cases that lack an identifiable EIF2AK3 mutation?
  attaches_to:
  - genetic#EIF2AK3 Biallelic Loss of Function
  rationale: >-
    In a functional study of 12 families, one patient had no EIF2AK3 involvement by
    both linkage and sequence data, and notably lacked the other variable
    manifestations of WRS, suggesting a distinct, uncharacterized genetic form. No
    second gene has been identified, so whether WRS is genetically heterogeneous
    remains open.
  evidence:
  - reference: PMID:15220213
    reference_title: "Wolcott-Rallison Syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient with no EIF2AK3 involvement did not have any of the other variable clinical manifestations associated with WRS, which supports the idea that the genetic heterogeneity between this variant form of WRS and EIF2AK3 WRS correlates with some clinical heterogeneity."
    explanation: >-
      The observation raising the possibility of genetic heterogeneity in WRS.
📚

References & Deep Research

References

1
PMID:21050479
Wolcott-Rallison syndrome.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
Wolcott-Rallison Syndrome: A Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 33 citations 2026-09-04T14:08:26.767489

Wolcott-Rallison Syndrome: A Comprehensive Research Report

1. Disease Information

Overview. Wolcott-Rallison syndrome (WRS) is a rare, autosomal recessive multisystem disorder caused by biallelic loss-of-function mutations in EIF2AK3, the gene encoding PERK (PKR-like Endoplasmic Reticulum Kinase). WRS is the most common monogenic cause of permanent neonatal diabetes mellitus (PNDM) in populations with frequent consanguinity, and is defined clinically by the triad of early-infantile insulin-dependent diabetes, multiple epiphyseal/skeletal dysplasia, and recurrent, often fatal, episodes of acute liver failure (Orphanet; PMC2991281).

Key identifiers: - OMIM: #226980 (Epiphyseal Dysplasia, Multiple, With Early-Onset Diabetes Mellitus) — gene locus EIF2AK3 OMIM 604032 - Orphanet: ORPHA:1667 - MONDO: MONDO:0009192 - MeSH: C536739 - DOID: DOID:0090060 - NCIT: NCIT:C131007 - UMLS: C0432217 - SNOMED CT: 254066006 - ICD-10-CM: E13 (Other specified diabetes mellitus) is the closest crosswalk (no dedicated WRS code) - Gene locus: EIF2AK3*, chromosome 2p11.2 (some sources cite 2p12) (Sources: MGI/OMIM disease page; OMIM #226980; GARD)

Synonyms: Multiple Epiphyseal Dysplasia with Early-Onset Diabetes Mellitus; EIF2AK3-Related Diabetes; WRS; PERK-related diabetes.

Evidence base: WRS knowledge derives almost entirely from aggregated case reports and small case series/cohorts (largest cohort n=28, Saudi Arabian systematic review; a German/Austrian registry sub-analysis n=11) rather than large prospective epidemiological studies, reflecting its ultra-rarity — fewer than 60–100 published cases worldwide as of the most recent reviews (Orphanet; PMC3679509).

2. Etiology

Causal factor. WRS is caused exclusively by biallelic (homozygous or compound heterozygous) loss-of-function mutations in EIF2AK3 — there is no known environmental, infectious, or multifactorial etiology for the primary syndrome itself, though intercurrent infections/illness act as precipitants of acute decompensation (see Mechanism, below) (PMC2991281).

Genetic risk factors: - To date, ~39 distinct EIF2AK3 mutations have been catalogued; 64% are frameshift or nonsense, 31% missense, with the remainder splice-site variants (PMC2991281). - Consanguinity is the dominant risk factor: the large majority of reported families are from the Middle East, North Africa, Pakistan, and Turkey. As of a 2013 tally, Saudi Arabia alone accounted for 27.7% (23/83) of all reported patients and 22.2% (12/54) of families worldwide (PMC3679509; Orphanet). - No recurrent "hot-spot"/founder mutation dominates globally, though specific mutations recur within specific consanguineous kindreds (e.g., p.V349Sfs3 in 3 families, p.W430X in 2 families in the Saudi cohort) (PMC4464042). - Population variant data: gnomAD catalogs ~1,294 EIF2AK3 variants; the overwhelming majority (1,270/1,294, ~98%) are ultra-rare (allele frequency <0.1%), consistent with strong purifying selection against loss-of-function alleles and a low population carrier frequency for pathogenic variants outside consanguineous/founder populations (source: GeneCards/gnomAD aggregation cited in search). - Genetic heterogeneity has been suggested — not all clinically diagnosed WRS cases have identifiable EIF2AK3* mutations, raising the possibility of a second, uncharacterized locus in a minority of cases (PMID:15220213, Diabetes 2004).

Risk-modifying/precipitating environmental factors (not causal, but triggers of crises): - Intercurrent viral/febrile illness is the principal trigger of acute hepatic failure episodes. - Hypoglycemia from overly tight glycemic control is an independent trigger of hepatic decompensation. - General anesthesia/anesthetic agents are explicitly flagged as a precipitant of acute aggravation due to hepatotoxicity and should be avoided when possible (PMC2991281). - Unnecessary medications and vaccinations are advised against as a precautionary/protective measure, presumably to minimize additional ER/hepatic stress burden, though this is empirical/consensus guidance rather than evidence from controlled study.

Protective factors: No genetic or environmental protective factors have been identified; missense (vs. truncating) genotype is associated with milder disease course and longer survival (see Genetics/Prognosis, below) but this is a modifier of severity, not a true "protective factor" against disease occurrence.

Gene-environment interaction: The core mechanistic interaction is that PERK loss-of-function removes the cell's adaptive buffer against ER stress, so ordinary physiological stressors (infection-associated cytokine/fever stress, insulin-secretory demand, hepatocyte protein-synthesis load during illness) that a wild-type cell would tolerate via the unfolded protein response (UPR) instead precipitate apoptosis in PERK-null cells — this is the mechanistic basis for why "trivial" childhood infections trigger life-threatening hepatic and pancreatic crises in WRS (PMC2991281; mechanism section below).

3. Phenotypes

Core triad

Phenotype HPO term (suggested) Onset Frequency
Permanent neonatal/infantile insulin-dependent diabetes HP:0008205 Neonatal insulin-dependent diabetes mellitus Typically <6 months (mean ~7.6 weeks in the largest cohort; range 1 day–30 months) 100% (defining feature)
Multiple epiphyseal dysplasia / skeletal dysplasia HP:0003400 Multiple epiphyseal dysplasia; HP:0003025 Metaphyseal dysplasia Later in infancy/childhood (may lag diabetes onset by months–years) Historically considered essential, but recent cohorts find it less frequent than previously assumed — absent in all 3 patients of one recent case series, and "lower than expected" in the largest Saudi cohort
Recurrent acute hepatic failure HP:0006554 Acute hepatic failure Episodic, triggered by intercurrent illness 85.7% of patients show liver dysfunction as the extra-pancreatic feature; among those, 22/24 (92%) progressed to acute hepatic failure

Additional systemic phenotypes (compiled from HPO/OMIM and cohort literature)

  • Hepatic/GI: Hepatomegaly (HP:0002240), jaundice (HP:0000952), ascites (HP:0001541), hepatic encephalopathy (HP:0002480), exocrine pancreatic insufficiency (HP:0001738)
  • Renal: Chronic kidney disease (HP:0012622), renal insufficiency (HP:0000083) — reported in ~6/28 (21%) in the largest cohort, often associated temporally with hepatitis episodes
  • Endocrine: Central/primary hypothyroidism (HP:0011771 / HP:0000821) — identified in 4/28 patients in the Saudi cohort (2 novel), now recognized as a genuine WRS feature rather than incidental
  • Hematologic: Decreased neutrophil count/neutropenia (HP:0001875), iron deficiency anemia (HP:0001891), increased lymphocyte count (HP:0100827), recurrent infections (HP:0002719)
  • Neurologic: Global developmental delay (HP:0001263), intellectual disability (HP:0001249), microcephaly (HP:0000252), seizure (HP:0001250), gait disturbance (HP:0001288), muscle weakness (HP:0001324); the 2024 zebrafish study also flags motor neuropathy and early neurodegeneration as part of the broader symptomatic spectrum (bioRxiv 2024.04.16.589737)
  • Cardiac: Atrial septal defect (HP:0001631), double outlet right ventricle (HP:0001719) — cardiac malformations occur but are not universal
  • Craniocervical (newly described, 2016): Os odontoideum with atlanto-axial instability was identified in a case series of 4 WRS patients not previously linked to the syndrome; 2/4 required spinal fusion for symptomatic instability — this is now recommended as an active screening item (PMC4748609)
  • Growth: Severe growth retardation/short stature (HP:0004322), decreased body weight (HP:0004325)
  • Ophthalmologic: Strabismus (HP:0000486)

Severity/progression: Skeletal disease (osteoporosis/osteopenia, epiphyseal dysplasia, fracture tendency) is progressive. Hepatic disease is episodic/relapsing — "every episode should be considered as potentially fatal," with individual crises lasting 3–20 days and resolving either to full recovery or death, unpredictably (PMC4464042). Diabetes is permanent and non-remitting from onset.

Quality of life impact: Not formally studied with standardized instruments (no EQ-5D/SF-36/PROMIS data identified in the literature); qualitatively, disease burden is dominated by recurrent hospitalization for hepatic crises, insulin pump dependence, and — in survivors — cumulative skeletal morbidity (fractures, craniocervical instability) and neurodevelopmental impairment.

4. Genetic/Molecular Information

Causal gene: EIF2AK3 (HGNC:3255), chromosome 2p11.2. Encodes PERK (also called PEK, pancreatic eIF2α kinase), a type I transmembrane ER-resident kinase.

Variant spectrum: ~39 distinct pathogenic mutations reported; 64% frameshift/nonsense (predicted null alleles), 31% missense, remainder splice-site (PMC2991281). Representative variants from recent literature: - c.1213-1214del (p.Lys405fs), exon 7 — frameshift - c.3087delC (p.Leu1030X), exon 16 — nonsense - c.2039_2040del (p.Thr680fs), exon 13 — frameshift (PMC10214929) - p.S991N, p.G1010D — novel missense variants associated with prolonged survival (one patient to 17.5 years) - p.V349Sfs*3, p.W430X — recurrent truncating variants in the Saudi founder cohort - p.I650T — associated with delayed diabetes onset (PMC4464042) - c.1805G>T (p.Gly602Val) — novel missense, 2025 case report (J Pediatr Endocrinol Metab 2025-0216) - c.205G>T — recurring in two unrelated families (PMC6425236)

Variant classification: Per ACMG/AMP framework, truncating (nonsense/frameshift) variants are generally classified pathogenic via loss-of-function mechanism given EIF2AK3's established disease mechanism; missense variants require functional validation (kinase-activity assays) for confident classification — several publications explicitly performed such functional studies (e.g., PMID:15220213, "clinical, genetic, and functional study").

Population frequency: gnomAD lists ~1,294 EIF2AK3 variants; ~98% are ultra-rare (<0.1% AF), ~14 are "rare" (0.1–1%), ~10 are "common" (>1%) — consistent with a gene under purifying selection and no population-level common pathogenic allele; carrier frequency is elevated specifically within consanguineous Middle Eastern/North African/South Asian kindreds due to founder effects rather than a panethnic high carrier rate.

Mechanism of pathogenicity: Loss-of-function — all disease mutations abolish or severely impair PERK's kinase activity toward eIF2α, eliminating its stress-buffering function (see Section 6).

Genotype-phenotype correlation: Limited overall, but the strongest reported correlation is that missense mutations are associated with significantly better survival than truncating mutations (Aldrian et al. 2024, Liver International: overall survival better with missense genotype, p=.013) (search summary of Liver Int 2024;44(3)).

Modifier genes: None formally established; disease severity variability even among siblings/patients with identical genotypes (see Case Series, Section 1) suggests unidentified modifiers or stochastic/environmental influence on crisis triggering.

Related but distinct EIF2AK3-associated phenotypes noted in GeneCards/OMIM annotations: metaphyseal chondrodysplasia (Schmid type)-like presentations and spondyloenchondrodysplasia with immune dysregulation have been loosely associated in some annotation databases, but WRS/multiple epiphyseal dysplasia with early-onset diabetes is the well-established, primary EIF2AK3 phenotype.

Epigenetics/chromosomal abnormalities: No epigenetic mechanism or chromosomal-scale abnormality (aneuploidy, translocation) has been implicated; WRS is a single-gene Mendelian disorder.

5. Environmental Information

WRS has no independent environmental or infectious etiology — it is monogenic. Environmental factors are relevant only as triggers of acute-on-chronic decompensation in already-affected individuals: - Intercurrent viral illness (implicated in nearly all documented hepatic crisis triggers) - Hypoglycemia (iatrogenic, from tight glycemic control) - General anesthesia/anesthetic hepatotoxicity - Possibly vaccination and additional medication burden (precautionary avoidance recommended, though causal evidence for vaccine-triggered crises specifically was not identified in the literature reviewed)

No infectious agent, toxin, or occupational/lifestyle exposure has been shown to cause WRS.

6. Mechanism / Pathophysiology

Ordered causal chain

  1. Biallelic loss-of-function mutation in EIF2AK3 (nonsense, frameshift, or destabilizing missense) → leads to absent or severely reduced PERK kinase activity in the ER-transmembrane sensor.
  2. Loss of PERK activity → results in failure to phosphorylate eukaryotic translation initiation factor 2-alpha (eIF2α) at Ser51 in response to ER protein-folding stress (this step is well-demonstrated biochemically — e.g., Nature Genetics 2000, ng0800_406; PMC8187601).
  3. Unphosphorylated eIF2α → fails to attenuate global cap-dependent mRNA translation, so the normal PERK-branch "translational brake" of the unfolded protein response (UPR) is lost, while the parallel IRE1 and ATF6 UPR arms remain at least partly intact but cannot compensate.
  4. Loss of translational attenuation, combined with failure to induce the ATF4→CHOP transcriptional program (which normally upregulates chaperones, proteases, and autophagy components to help clear misfolded protein) → leads to accumulation of unresolved misfolded/unfolded protein in the ER lumen — chronic, unbuffered ER stress — in any cell type with high secretory/synthetic demand.
  5. Chronic ER stress in these high-demand tissues → triggers apoptotic cell death via CHOP-independent and stress-kinase pathways, disproportionately affecting:
  6. Branch A — pancreatic β-cells: PERK is specifically required during fetal and early neonatal life for β-cell proliferation, differentiation, and proinsulin trafficking/quality control in the secretory pathway. PERK-null β-cells fail to expand postnatally, show low β-cell mass, and cannot properly process/traffic proinsulin, culminating in permanent neonatal-onset insulin deficiency (Cell Metab 2006, PMID:17141632; Diabetes 2009, db09-1064; PMC2749809).
  7. Branch B — hepatocytes: at baseline hepatocytes tolerate the deficit, but during intercurrent illness/fever (increased secretory/synthetic demand and cytokine stress) the unbuffered ER stress load exceeds the cell's capacity → triggers acute hepatocyte apoptosis/necrosis → clinical acute hepatic failure. This explains why hepatic crises are episodic and infection-triggered rather than constant — the deficit is a loss of adaptive reserve, not baseline organ failure.
  8. Branch C — chondrocytes/osteoblasts and bone: PERK also has a constitutive, non-redundant role in bone homeostasis — it regulates osteoclast differentiation/function (activated during RANKL-induced osteoclastogenesis) and is required for normal ossification-center development. Perk-knockout mice show reduced cortical and trabecular bone density at birth and a stunted secondary ossification center of the proximal tibia, mirroring human epiphyseal dysplasia and osteoporosis (Cell Death Dis 2020, s41419-020-03046-z; PMC8016635).
  9. Branch D — other tissues (thyroid, kidney, CNS, exocrine pancreas, marrow) → contributes to the variable additional phenotypes (central/primary hypothyroidism, renal insufficiency, neurodevelopmental delay/seizures, exocrine pancreatic insufficiency, neutropenia) via the same loss-of-adaptive-capacity mechanism, though tissue-specific mechanistic detail is less well worked out than for β-cell and hepatocyte injury.
  10. Recurrent hepatic apoptotic crises, superimposed skeletal fragility, and multi-organ vulnerability → culminate in the clinical natural history of WRS: high early mortality (predominantly from liver failure), with survivors accumulating progressive skeletal, endocrine, and neurodevelopmental morbidity.

Where inference substitutes for direct human demonstration: The β-cell developmental mechanism (branch A) and the bone-homeostasis mechanism (branch C) are demonstrated principally in Perk knockout mouse models and are inferred, not directly demonstrated, in human WRS tissue — human data are limited to genetics, biochemistry of patient-derived material in a few functional studies, and clinical/radiographic phenotyping. The 2024 zebrafish PERK-inhibition model provides an additional, largely concordant, cross-species line of evidence (see Model Organisms, below).

Molecular pathway / GO term suggestions

  • Molecular function: GO:0004694 eukaryotic translation initiation factor 2alpha kinase activity (loss of function)
  • Biological process: GO:0034976 response to endoplasmic reticulum stress; GO:0036498 IRE1-mediated unfolded protein response (intact/compensatory); GO:0036499 PERK-mediated unfolded protein response (lost); GO:0006446 regulation of translational initiation; GO:0030282 bone mineralization; GO:0030316 osteoclast differentiation
  • Cellular component: GO:0005789 endoplasmic reticulum membrane (site of PERK localization)

Cell types (CL terms)

  • CL:0000169 type B pancreatic cell (β-cell) — primary target, developmental failure
  • CL:0000182 hepatocyte — episodic apoptotic injury
  • CL:0000092 osteoclast; CL:0000062 osteoblast — bone homeostasis defect
  • CL:0000037 hematopoietic stem cell / CL:0000775 neutrophil — neutropenia (mechanism less characterized)

Molecular profiling / omics

No large-scale transcriptomic, proteomic, or single-cell datasets specific to human WRS patient tissue were identified in this search — the mechanistic evidence base relies on candidate-gene biochemistry (PERK kinase assays, eIF2α phosphorylation assays) and animal-model transcriptomic/histologic phenotyping rather than patient-derived multi-omics.

7. Anatomical Structures Affected

Organ level (primary): - Pancreas (endocrine — islet β-cells; also exocrine insufficiency reported) — UBERON:0001264 - Liver — UBERON:0002107 - Skeletal system — long-bone epiphyses/metaphyses, vertebral column (including craniocervical junction/odontoid process) — UBERON:0001434 (skeletal system); UBERON:0002514 (epiphysis)

Secondary/complication-level organ involvement: - Kidney (chronic kidney disease/renal insufficiency, often in the context of hepatic crises) — UBERON:0002113 - Thyroid (central and primary hypothyroidism) — UBERON:0002046 - Central nervous system (developmental delay, intellectual disability, seizures, microcephaly) — UBERON:0001017 - Bone marrow/hematopoietic system (neutropenia, anemia) — UBERON:0002371 - Heart (septal defects, outflow tract anomalies in a subset) — UBERON:0000948 - Cervical spine/craniocervical junction — atlanto-axial joint, odontoid process — UBERON:0004736 (atlanto-axial joint) — newly recognized site of pathology (os odontoideum)

Tissue/cell level: - Pancreatic islet β-cells (CL:0000169) — developmental failure, apoptosis - Hepatocytes (CL:0000182) — recurrent apoptotic/necrotic injury - Growth-plate chondrocytes and osteoblasts/osteoclasts — impaired ossification and bone turnover

Subcellular level: - Endoplasmic reticulum (GO:0005783) — site of the primary molecular lesion (PERK is an ER transmembrane sensor)

Localization/laterality: Skeletal involvement is typically bilateral/symmetric (multiple epiphyseal dysplasia affecting multiple joints); craniocervical instability (os odontoideum) is a midline structural anomaly.

8. Temporal Development

Onset: Congenital predisposition with infantile clinical onset — diabetes typically manifests before 6 months of age (mean ~7.6 weeks in the largest cohort; documented range 1 day to 30 months) (PMC4464042). Skeletal dysplasia and hepatic crises generally emerge later, over the first years of life, and are not necessarily present at diabetes diagnosis (in one 3-patient case series, skeletal survey was unremarkable in all three at initial evaluation) (PMC10214929).

Progression: - Diabetes: permanent from onset, non-remitting, requires lifelong insulin. - Skeletal disease: progressive — osteopenia/osteoporosis and epiphyseal dysplasia worsen over childhood; craniocervical instability (os odontoideum) is a later, potentially progressive structural complication. - Hepatic disease: episodic/relapsing rather than continuously progressive — discrete crises (3–20 days each) triggered by intercurrent illness, interspersed with periods of normal or near-normal liver function; each episode carries independent mortality risk ("every episode should be considered as potentially fatal") (PMC4464042). - Disease course pattern: best characterized as chronic-with-superimposed-acute-crises — a stable multisystem baseline (diabetes, growth failure, evolving skeletal disease) punctuated by unpredictable, life-threatening hepatic decompensations.

Critical periods: The fetal/early-neonatal window is a defined critical period for PERK-dependent β-cell mass expansion (established in mouse models), explaining the very early and permanent (non-recoverable) nature of the diabetes. Intercurrent-illness episodes throughout childhood represent recurring "critical windows" of vulnerability for fatal hepatic decompensation.

Duration/course: Chronic, lifelong — no spontaneous remission of any component described. Disease is fundamentally not self-limited.

9. Inheritance and Population

Epidemiology: Ultra-rare — fewer than 60–100 cases reported worldwide in the literature to date; true prevalence is unknown and likely underestimated due to early death before diagnosis in some cases (Orphanet). WRS is nonetheless recognized as the single most common cause of permanent neonatal diabetes mellitus (PNDM) in consanguineous populations (PMC3679509).

Inheritance pattern: Autosomal recessive; 25% recurrence risk for future siblings of an affected proband; carrier (heterozygous) parents are clinically unaffected (PMC2991281).

Penetrance: Effectively complete for the diabetes component when biallelic loss-of-function variants are present, given uniform early presentation across cohorts; penetrance/expressivity of skeletal and hepatic components is more variable (e.g., skeletal survey normal at diagnosis in several reported cases despite confirmed genotype).

Expressivity: Variable, even among siblings/patients with the same or similar genotype — documented cases show some family members with only diabetes and mild or absent skeletal disease, and marked variability in hepatic crisis severity and timing; genotype (missense vs. truncating) is the only established modifier identified to date.

Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).

Germline mosaicism: Not specifically documented in the literature reviewed for this report.

Founder effects: Yes — recurrent identical mutations within specific consanguineous kindreds/regions (e.g., p.V349Sfs*3, p.W430X recurring across multiple Saudi families) are consistent with regional founder alleles rather than panethnic hot-spot mutations (PMC4464042).

Consanguinity role: Central — the overwhelming majority of reported cases arise from consanguineous unions; consanguinity is explicitly noted in essentially all detailed case reports reviewed (e.g., all three patients in the PMC10214929 case series had consanguineous parents, as did the 2025 case report of p.Gly602Val).

Carrier frequency: Not formally established at a population level in the sources reviewed; presumed elevated specifically within consanguineous Middle Eastern/North African/South Asian communities based on founder-mutation recurrence, but no population-representative carrier-frequency study was identified.

Population demographics: - Geographic distribution: Middle East, North Africa, Pakistan, and Turkey are disproportionately represented; Saudi Arabia alone contributed 22–28% of all reported cases/families as of a 2013 tally. - Sex ratio: Male predominance noted in the largest cohort (67% male, n=28) — this may partly reflect ascertainment/reporting rather than a true biological sex effect, as no sex-linked mechanism is plausible for an autosomal recessive disorder. - Age distribution: Skewed heavily toward infancy/early childhood at both diagnosis and death; mean age at death 5.8 years in the largest cohort, though rare long-term survivors are documented into adulthood (see Prognosis).

10. Diagnostics

Clinical suspicion: WRS should be suspected in any infant with permanent neonatal/early-infantile insulin-dependent diabetes, particularly when accompanied by (or later developing) skeletal dysplasia and/or episodes of unexplained acute liver failure, especially in the setting of parental consanguinity (PMC2991281).

Laboratory tests: - HbA1c (elevated at diagnosis, typically 9–12% in reported cases) - Liver enzymes (markedly elevated during hepatic crises — one cohort reported transaminases ranging 242 to 50,000 IU/L, mean 8,620 IU/L) - Bilirubin (jaundice during crises) - Absence of β-cell autoantibodies (GAD, IA-2, ICA) — a key diagnostic discriminator from autoimmune type 1 diabetes - Normal blood calcium and phosphorus (helps distinguish from other skeletal dysplasia syndromes) - Renal function panel (during and between hepatic episodes) - Thyroid function tests (screen for central/primary hypothyroidism) - Complete blood count (screen for neutropenia, anemia)

Imaging: - Skeletal survey / radiographs for epiphyseal/metaphyseal dysplasia, osteopenia - Cervical spine imaging (flexion-extension views, CT/MRI) — now recommended given the described association with os odontoideum and atlanto-axial instability - Abdominal ultrasound (hepatomegaly during crises)

Genetic testing: - Molecular sequencing of EIF2AK3 (single-gene sequencing, or as part of a neonatal diabetes/monogenic diabetes gene panel) is the confirmatory test. - Given the phenotypic overlap and the imperative for early diagnosis, whole-exome or targeted PNDM gene-panel sequencing is generally the more practical first-line genetic test in a neonate/infant presenting with permanent diabetes, since it simultaneously interrogates KCNJ11, ABCC8, INS, GLIS3, EIF2AK3, and other PNDM genes. - Parental testing confirms carrier status and supports genetic counseling / prenatal diagnosis in future pregnancies.

Differential diagnosis: | Condition | Distinguishing feature | |---|---| | Autoimmune Type 1 diabetes | Presence of β-cell autoantibodies (GAD, IA-2, ICA); WRS is autoantibody-negative | | Transient neonatal diabetes | Hyperglycemia resolves; WRS diabetes is permanent | | KCNJ11/ABCC8-related PNDM (e.g., DEND syndrome) | Neuro-developmental/motor features but no liver disease; often sulfonylurea-responsive, unlike WRS | | GLIS3-related neonatal diabetes | Associated with congenital (not later-onset central) hypothyroidism, congenital glaucoma | | Other PNDM etiologies (pancreatic agenesis, IPEX, etc.) | Generally lack the combined skeletal + hepatic phenotype | (Source: PMC2991281)

Screening: No formal population newborn-screening program exists for WRS (it is not detected by standard newborn metabolic screening panels). In high-risk consanguineous populations/regions, targeted carrier screening and cascade testing within affected families is the practical screening strategy; prenatal diagnosis is available once the familial mutation is known.

11. Outcome/Prognosis

Mortality: Historically poor prognosis. In the largest cohort (n=28), 46.4% of patients were deceased at a mean age of death of 5.8 years; liver failure was the cause of death in essentially all deceased patients (13/13 in the sub-analysis of the 22 hepatic-failure episodes with a fatal outcome available) (PMC4464042). In the 2024 systematic review/follow-up study (Aldrian et al.), liver failure was the leading cause of death in 17.9% of the pooled cohort, and overall survival was significantly better with missense genotype (p=.013) (Liver Int 2024;44(3)).

Historical natural-history data: Of patients with known age at death in an earlier review, only 3/19 survived to age 10 or older; two exceptional long-term survivors reached ages 32 and 35 years (PMC2991281). A missense variant (p.S991N) has separately been associated with survival to 17.5 years (PMC4464042).

Impact of transplantation on survival: In the transplant sub-cohort of the 2024 Aldrian systematic review, 1-, 5-, and 10-year patient survival rates were 89.4%, 65.5%, and 53.1%, respectively, and survival was significantly better in transplanted vs. non-transplanted patients (p=.0057) — the strongest available evidence that liver (or multi-organ) transplantation meaningfully improves long-term survival in WRS (Liver Int 2024;44(3)).

Morbidity in survivors: Progressive skeletal disease (fractures, growth failure), craniocervical instability, developmental delay/intellectual disability, chronic kidney disease, and hypothyroidism accumulate over time even in patients who survive acute hepatic crises. Post-transplant, skeletal complications have been reported to persist despite resolution of hepatic and glycemic issues (one 6-year post-transplant follow-up: normal liver function, improved HbA1c to 7.8%, no recurrent hepatitis, but ongoing skeletal complications) (PMC4464042).

Prognostic factors: - Genotype: missense mutations associated with milder disease and longer survival vs. truncating (nonsense/frameshift) mutations. - Transplantation status: markedly improves survival. - Frequency/severity of hepatic crises: the dominant determinant of mortality; "every episode should be considered as potentially fatal."

12. Treatment

Pharmacotherapy — diabetes management: - Insulin therapy is mandatory and lifelong; in the German/Austrian DPV registry sub-analysis (n=11), 90% of patients used continuous subcutaneous insulin infusion (CSII/insulin pump), with insulin requirements (~0.7 IU/kg/day at diagnosis and follow-up) comparable to well-controlled type 1 diabetes in preschoolers (PMC7178620). Suggested NCIT term: NCIT:C15986 (Pharmacotherapy) with therapeutic_agent insulin. - Glycemic targets must be individualized and relatively liberal — tight control is explicitly discouraged because hepatic dysfunction impairs gluconeogenesis, making these patients disproportionately vulnerable to severe hypoglycemia, which itself can trigger hepatic decompensation. Reflecting this, glycemic control in the DPV cohort was suboptimal by standard pediatric targets (median HbA1c 8.0%; only 27% achieved <7.5%) — but this likely represents an appropriate clinical trade-off rather than a failure of care (PMC7178620). - Diabetes-related complications in this cohort: 70% presented in DKA at diagnosis, 10% had recurrent DKA, and 40% experienced at least one severe hypoglycemic episode during follow-up — substantially higher hypoglycemia rates than general pediatric T1D cohorts (1.9–2.8%), attributed to impaired hepatic glucose counter-regulation.

Surgical/transplantation: - Liver transplantation — the single most impactful intervention demonstrated to date; used alone or combined with pancreas and/or kidney transplantation for combined organ failure. NCIT:C15289 (Organ Transplantation). - First reported successful WRS liver transplant patient maintained normal liver function >6 years post-transplant with improved glycemic control and no recurrent hepatitis (PMC4464042). - Combined en bloc liver-pancreas-kidney transplantation has been performed for patients with concurrent acute liver and renal failure, using techniques such as a donor aortic conduit for graft inflow (AJT 2015, Tzakis et al.; additional case reports of en bloc multiorgan transplant). - In the 2024 systematic review, transplantation (6 liver-only, 1 combined liver-pancreas, 2 combined liver-pancreas-kidney) was associated with significantly improved survival (1-/5-/10-year: 89.4%/65.5%/53.1%). - Orthopedic management: surgical stabilization for symptomatic craniocervical instability (spinal fusion performed in 2/4 patients with os odontoideum in the relevant case series) — NCIT:C16186 (Orthopedic Surgical Procedure).

Supportive/multisystem care: - Aggressive, rapid supportive management of acute hepatic failure episodes (the dominant driver of mortality) — NCIT:C15747 (Supportive Care). - Monitoring and treatment of hypothyroidism (levothyroxine replacement), renal dysfunction, neutropenia/infection risk. - Orthopedic surveillance and fracture management for progressive osteoporosis/skeletal dysplasia. - Avoidance of unnecessary general anesthesia and minimization of non-essential medications/vaccines as precautionary measures against triggering hepatic decompensation. - Growth and nutritional support; developmental/rehabilitative services (physical, occupational, speech therapy as needed) — NCIT:C15302 (Physical Therapy).

Experimental/investigational — no disease-modifying therapy is currently approved. Literature identifies plausible but unproven strategies targeting the underlying ER-stress mechanism: - Chemical chaperones (mechanism: reduce ER protein-misfolding burden, potentially compensating for loss of the PERK stress-response arm) — proposed but not clinically tested in WRS specifically (PMC2991281). - GLP-1 receptor agonists — proposed as a potential ER-stress-reducing/β-cell-protective strategy, again by analogy to broader ER-stress diabetes biology rather than WRS-specific trials. - ISRIB and related Integrated Stress Response (ISR) modulators — mechanistically relevant to the eIF2α/ISR pathway broadly, but caution is warranted: because WRS already reflects a deficient PERK/ISR response, further ISR inhibition (as ISRIB does) could theoretically worsen rather than help ER-stress-related pathology in this specific condition — this is a mechanistic caution raised in the general ISR-therapeutics literature (Science 2019, aat5314; PNAS 2019, ISRIB), not a WRS-specific clinical finding. - No gene therapy, RNA-based therapy, or targeted small-molecule PERK-agonist strategy has reached clinical development for WRS specifically as of this search.

Clinical trials: No active interventional clinical trials specific to Wolcott-Rallison syndrome were identified in this search (consistent with its ultra-rarity); management is guided by case series/registry data (e.g., the German/Austrian DPV database) rather than randomized trial evidence.

13. Prevention

Primary prevention: Not applicable in the sense of preventing occurrence in an individual once conceived (monogenic recessive disorder); the only true primary-prevention lever is reproductive/genetic counseling in at-risk consanguineous families (25% recurrence risk per pregnancy for two carrier parents) — NCIT:C15240 (Genetic Counseling).

Genetic/reproductive prevention: - Carrier testing of parents/extended family once a proband's mutation is identified. - Prenatal diagnosis via genotyping of the known familial mutation(s) is available for future pregnancies (PMC2991281). - Preimplantation genetic diagnosis is a logical extension for known-carrier couples, though not explicitly documented as reported/utilized for WRS in the literature reviewed.

Secondary prevention (early detection): Early molecular diagnosis in an infant presenting with permanent neonatal diabetes — particularly from a consanguineous family — enables anticipatory screening for skeletal dysplasia, craniocervical instability, hepatic dysfunction, thyroid dysfunction, and renal dysfunction before they become symptomatic, and allows for planned rather than reactive management of hepatic crises.

Tertiary prevention (preventing complications once diagnosed): - Individualized, deliberately non-aggressive glycemic targets to minimize hypoglycemia-triggered hepatic decompensation. - Avoidance of unnecessary general anesthesia and non-essential medications. - Active surveillance for and prophylactic management of craniocervical instability (screening cervical spine imaging). - Prompt, aggressive supportive treatment at the first sign of intercurrent illness to try to blunt progression to hepatic crisis. - Consideration of pre-emptive/early liver (or multi-organ) transplantation referral in patients with recurrent severe hepatic crises, given the substantial survival benefit demonstrated in the 2024 systematic review.

Screening programs: No population-based newborn screening exists; screening is currently limited to targeted cascade testing in known-carrier families/high-prevalence consanguineous communities.

14. Other Species / Natural Disease

Naturally occurring disease in other species: No naturally occurring veterinary/companion-animal correlate of Wolcott-Rallison syndrome was identified in this search (no OMIA entry or veterinary case series surfaced). WRS, as characterized, is essentially a human-described disease entity tied to specific EIF2AK3 loss-of-function alleles arising in consanguineous human populations.

Orthologous gene: Mouse ortholog Eif2ak3 (MGI:1341830) is well characterized and highly conserved with human EIF2AK3; the 2024 zebrafish study explicitly notes "high similarity between human and zebrafish PERK," supporting cross-species conservation of PERK structure and function (bioRxiv 2024.04.16.589737; MGI:1341830).

Comparative biology: The core PERK/eIF2α/UPR pathway is deeply evolutionarily conserved (present in mouse, zebrafish, and more broadly across eukaryotes), and its role in β-cell development, hepatocyte stress tolerance, and bone homeostasis appears conserved across the mammalian and zebrafish models studied, supporting strong translational validity of these model systems for mechanism (though not necessarily for the full multisystem human clinical phenotype — see Model Organisms).

Transmission/zoonotic potential: Not applicable — WRS is a non-communicable monogenic disorder.

15. Model Organisms

Genetic mouse models

  • Global Eif2ak3 (Perk) knockout mice (MGI:1341830) are the principal and best-validated model:
  • Recapitulates: neonatal-onset diabetes via failed β-cell developmental expansion and impaired proinsulin trafficking/secretion (Cell Metab 2006, PMID:17141632; Diabetes 2009, db09-1064); severe osteopenia with reduced cortical/trabecular bone density and a stunted secondary ossification center of the proximal tibia at birth, closely mirroring human epiphyseal dysplasia and osteoporosis (Cell Death Dis 2020; PMC8016635).
  • PERK is shown to be specifically required during the fetal/early-neonatal window for β-cell proliferation and differentiation, directly explaining the permanence and very early onset of human WRS diabetes — a key mechanistic insight derived from this model that is not directly testable in human tissue.
  • Acute/conditional PERK ablation models (BMC Mol Cell Biol 2009, link.springer.com/article/10.1186/1471-2121-10-61) show that even acute (post-developmental) PERK loss causes ER dysfunction, reduced insulin secretion, and reduced β-cell proliferation — indicating PERK also has an ongoing homeostatic role beyond the developmental window.
  • Limitations: global knockout mice do not fully reproduce the episodic, infection-triggered hepatic failure pattern seen in humans as a primary readout in the cited literature (the hepatic phenotype is less emphasized in the mouse literature reviewed than the pancreatic and skeletal phenotypes), and mouse models cannot capture some human-specific features (e.g., craniocervical os odontoideum has not been reported in mouse models).

Zebrafish model (pharmacological PERK inhibition, 2024)

  • Model: wild-type zebrafish treated with the selective PERK inhibitor GSK2606414, chosen because zebrafish PERK shows high sequence/functional similarity to human PERK (bioRxiv 2024.04.16.589737).
  • Recapitulates: growth and skeletal developmental defects, neuromuscular and cardiac deficiencies, and — notably — decreased pancreatic β-cell mass with disrupted glucose homeostasis, reproducing a diabetic phenotype pharmacologically rather than genetically.
  • Significance: this is the newest (2024) addition to the WRS model-organism toolkit and the first reported use of a pharmacological, rather than purely genetic, PERK-loss model to reproduce the multisystem WRS phenotype, offering a scalable platform for future small-molecule/chaperone-based therapeutic screening.
  • Relationship to fidelity/limitations: as a pharmacological (not genetic) and developmental (acute exposure, not lifelong deficiency) model, it models PERK loss of function broadly rather than any single patient-specific EIF2AK3 allele, and — being zebrafish — cannot model the human-specific craniocervical or long-term hepatic-failure natural history; it is best understood as a developmental-biology and drug-screening model, complementary to the mouse knockout's stronger fidelity for the β-cell/bone developmental mechanism.

Resources

  • MGI: Eif2ak3 gene page (MGI:1341830) — mouse allele/phenotype resource
  • No dedicated WRS entry found in OMIA (no naturally occurring animal disease correlate)

Summary of Suggested Ontology Bindings for KB Curation

Category Suggested term
Disease MONDO:0009192; OMIM:226980; ORPHA:1667
Causal gene hgnc EIF2AK3 (verify current HGNC ID before binding)
Core phenotype — diabetes HP:0008205
Core phenotype — skeletal dysplasia HP:0003400
Core phenotype — hepatic failure HP:0006554
Cell type — β-cell CL:0000169
Cell type — hepatocyte CL:0000182
Cell type — osteoclast CL:0000092
Biological process — ER stress response GO:0034976
Biological process — PERK-mediated UPR GO:0036499
Anatomy — pancreas UBERON:0001264
Anatomy — liver UBERON:0002107
Treatment — insulin/pharmacotherapy NCIT:C15986
Treatment — organ transplantation NCIT:C15289
Treatment — orthopedic surgery NCIT:C16186
Treatment — genetic counseling NCIT:C15240

(All ontology IDs above should be independently re-verified via OAK/just validate-terms before use in a dismech KB entry, per project convention — this report is a research lead, not pre-validated curation content.)

Sources